{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f3e28e16",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                    id   source  \\\n",
      "0     Medical-73586ddc  Medical   \n",
      "1     Medical-a8bad1cf  Medical   \n",
      "2     Medical-422500d5  Medical   \n",
      "3     Medical-6d2a190d  Medical   \n",
      "4     Medical-5ad931db  Medical   \n",
      "...                ...      ...   \n",
      "2057  Medical-83c906e0  Medical   \n",
      "2058  Medical-d168a555  Medical   \n",
      "2059  Medical-fe801cec  Medical   \n",
      "2060  Medical-9210668e  Medical   \n",
      "2061  Medical-5a1e917c  Medical   \n",
      "\n",
      "                                               question  \\\n",
      "0          What is the most common type of skin cancer?   \n",
      "1     From which cell type does basal cell carcinoma...   \n",
      "2     Which anatomical locations are most commonly a...   \n",
      "3     What is the primary risk factor for basal cell...   \n",
      "4     How does fair skin affect the risk of developi...   \n",
      "...                                                 ...   \n",
      "2057  You are an oncologist preparing a referral let...   \n",
      "2058  Imagine you are a medical intern tasked with w...   \n",
      "2059  You are a patient advocate tasked with draftin...   \n",
      "2060  Transform the clinical facts on metastatic bre...   \n",
      "2061  Assume the role of a genetic counselor. Prepar...   \n",
      "\n",
      "                                                 answer        question_type  \\\n",
      "0     Basal cell carcinoma (BCC) is the most common ...       Fact Retrieval   \n",
      "1     Basal cell carcinoma arises from basal cells i...       Fact Retrieval   \n",
      "2     BCC most commonly develops in sun-exposed area...       Fact Retrieval   \n",
      "3     UV radiation exposure is a primary risk factor...       Fact Retrieval   \n",
      "4                  Fair skin increases the risk of BCC.       Fact Retrieval   \n",
      "...                                                 ...                  ...   \n",
      "2057  Dear Multidisciplinary Team,\\n\\nI am referring...  Creative Generation   \n",
      "2058  Discharge Summary:\\n\\nDiagnosis: Stage III inf...  Creative Generation   \n",
      "2059  Public Health Notice: Protect Yourself—Know th...  Creative Generation   \n",
      "2060  SOAP Progress Note\\n\\nSubjective: The patient ...  Creative Generation   \n",
      "2061  Genetic Counseling Summary:\\n\\nYou have tested...  Creative Generation   \n",
      "\n",
      "                                               evidence  \\\n",
      "0     Basal cell carcinoma (BCC) is the most common ...   \n",
      "1     Basal cell carcinoma arises from basal cells.;...   \n",
      "2     BCC most commonly develops in sun-exposed area...   \n",
      "3     UV radiation exposure is a primary risk factor...   \n",
      "4                  Fair skin increases the risk of BCC.   \n",
      "...                                                 ...   \n",
      "2057  The patient is a 45-year-old female.; The pati...   \n",
      "2058  The diagnosis is Stage III inflammatory breast...   \n",
      "2059  Breast cancer is a carcinoma that starts in th...   \n",
      "2060  The patient reports persistent bone pain.; The...   \n",
      "2061  The patient has tested positive for a BRCA1 mu...   \n",
      "\n",
      "                                     evidence_relations  \n",
      "0     Basal cell carcinoma (BCC) is the most common ...  \n",
      "1     BCC arises from basal cells in the lower part ...  \n",
      "2     BCC most commonly develops in sun-exposed area...  \n",
      "3     UV radiation exposure is a primary risk factor...  \n",
      "4     Fair skin, light hair, and light eye color inc...  \n",
      "...                                                 ...  \n",
      "2057  Invasive ductal carcinoma is the most common t...  \n",
      "2058  Inflammatory breast cancer (IBC) is a rare, ag...  \n",
      "2059  Breast cancer is a carcinoma that starts in th...  \n",
      "2060  Metastatic breast cancer (MBC) is breast cance...  \n",
      "2061  BRCA1 and BRCA2 mutations increase the risk of...  \n",
      "\n",
      "[2062 rows x 7 columns]\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "q = pd.read_parquet(r\"C:\\Users\\HP\\Desktop\\Projects\\NodeRAG\\GraphRAG-Benchmark\\Datasets\\Questions\\medical_questions.parquet\")\n",
    "print(q)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "f40463d6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Fact Retrieval', 'Complex Reasoning', 'Contextual Summarize',\n",
       "       'Creative Generation'], dtype=object)"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "q[\"question_type\"].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "0d90787f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "id",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "source",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "question",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "question_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "evidence",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "evidence_relations",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "7277a6b8-9c56-4aa9-80bf-1de5bedb49c3",
       "rows": [
        [
         "1896",
         "Medical-fe3240a4",
         "Medical",
         "Imagine you are a dermatology attending receiving a new patient referral for a suspicious lesion on the face. Write a consult note summarizing the key risk factors, diagnostic steps, and initial management plan for suspected basal cell carcinoma, referencing current clinical practice guidelines.",
         "Consult Note:\n\nA new patient was referred for evaluation of a suspicious lesion on the left cheek. Key risk factors for basal cell carcinoma (BCC) in this patient include significant cumulative sun exposure, fair skin phenotype, and a personal history of skin cancer. On physical examination, the lesion is located on a sun-exposed area of the face and appears as a shiny, pearly papule with rolled borders, consistent with classic BCC morphology.\n\nDiagnostic steps will follow current clinical practice guidelines and include: (1) a comprehensive skin examination to assess for additional lesions, (2) a detailed medical and family history to identify further risk factors or hereditary syndromes, and (3) a skin biopsy of the lesion to establish a definitive diagnosis. Imaging studies may be considered if there is clinical suspicion for perineural invasion or deep tissue involvement.\n\nIf the diagnosis of BCC is confirmed, the initial management plan will prioritize surgical excision, which is the standard first-line treatment. The patient will be counseled regarding the risk of recurrence and the importance of ongoing surveillance, including annual full skin examinations, as recommended by current guidelines. Additional education will be provided on sun protection and self-skin examination to reduce future risk.",
         "Creative Generation",
         "The patient presents with a suspicious lesion on the left cheek.; Key risk factors for basal cell carcinoma include significant sun exposure.; Key risk factors for basal cell carcinoma include fair skin.; Key risk factors for basal cell carcinoma include a personal history of skin cancer.; The lesion appears as a shiny, pearly bump with rolled borders.; The diagnostic plan includes a thorough skin exam.; The diagnostic plan includes a detailed medical and family history.; The diagnostic plan includes performing a skin biopsy to confirm basal cell carcinoma.; Imaging may be considered if there is suspicion of deep tissue involvement.; Surgical excision is proposed as the first-line treatment if basal cell carcinoma is confirmed.; The patient will be counseled on recurrence risk.; The patient will be advised on the importance of annual full skin exams for follow-up.",
         "BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Fair skin, light hair, and light eye color increase the risk of BCC; History of skin cancer or family history increases risk of BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Surgery is the most common treatment for BCC; Follow-up includes full skin exams with a doctor at least once a year"
        ],
        [
         "1897",
         "Medical-8f5233d5",
         "Medical",
         "You are a general practitioner drafting a discharge summary for a patient treated for basal cell carcinoma on the scalp. Transform the clinical facts into a formal discharge summary, ensuring inclusion of risk factors, clinical presentation, diagnostic workup, treatment, and follow-up recommendations.",
         "Discharge Summary:\n\nDiagnosis: Basal cell carcinoma (BCC) of the scalp\n\nSummary: The patient presented with a shiny bump with rolled borders on the scalp, a sun-exposed area. Risk factors include prolonged UV radiation exposure, fair skin, and older age. Diagnostic evaluation included a physical and skin exam, as well as a skin biopsy confirming BCC. The patient underwent surgical excision of the lesion. No evidence of recurrence or metastasis was found. The patient is advised to attend full skin exams at least annually for follow-up and to practice sun protection to reduce recurrence risk.",
         "Creative Generation",
         "The patient was diagnosed with basal cell carcinoma of the scalp.; The patient presented with a shiny bump with rolled borders on the scalp.; The lesion is located in a sun-exposed area.; Risk factors for basal cell carcinoma include prolonged UV radiation exposure.; Risk factors for basal cell carcinoma include fair skin.; Risk factors for basal cell carcinoma include older age.; Diagnostic evaluation included a physical and skin exam.; Diagnostic evaluation included a skin biopsy confirming basal cell carcinoma.; The patient underwent surgical excision of the lesion.; No evidence of recurrence or metastasis was found.; The patient is advised to attend full skin exams at least annually for follow-up.; The patient is advised to practice sun protection to reduce recurrence risk.",
         "BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Older age is associated with higher risk of BCC; Fair skin, light hair, and light eye color increase the risk of BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Surgery is the most common treatment for BCC; Follow-up includes full skin exams with a doctor at least once a year"
        ],
        [
         "1898",
         "Medical-c9c108e1",
         "Medical",
         "Assume the role of a patient who has just been diagnosed with basal cell carcinoma. Write a letter to your family explaining what the diagnosis means, the likely causes, the treatment you will receive, and what you will need to do to monitor your health going forward, using evidence from the clinical guideline.",
         "Dear Family,\n\nI wanted to let you know that I have been diagnosed with basal cell carcinoma (BCC), which is the most common type of skin cancer. BCC arises from basal cells in the lower part of the skin’s outer layer (epidermis) and most often develops in areas that have been exposed to the sun, such as the face, head, and neck. The main risk factors for BCC include fair skin, frequent or intense sun (UV) exposure, a personal or family history of skin cancer, and factors like previous radiation therapy or immune suppression. My diagnosis was made after a thorough skin examination and a biopsy of the suspicious area. The standard and most effective treatment is surgery to remove the cancerous tissue, and my care team will guide me through this process. After treatment, I will need to have regular full skin exams with my doctor at least once a year to monitor for any recurrence or new skin cancers. Moving forward, I will be vigilant about sun protection—using sunscreen, wearing protective clothing, and avoiding tanning beds—to help reduce my risk. I am also encouraged to stay organized with my medical records and communicate openly with my care team. Please know that BCC is highly treatable, especially when detected early, and I am taking all recommended steps to ensure the best possible outcome.",
         "Creative Generation",
         "The patient has been diagnosed with basal cell carcinoma.; Basal cell carcinoma is the most common type of skin cancer.; Basal cell carcinoma develops from basal cells in the lower part of the skin’s outer layer.; Basal cell carcinoma usually occurs in areas exposed to the sun, like the face or scalp.; Risk factors for basal cell carcinoma include fair skin.; Risk factors for basal cell carcinoma include significant sun or UV exposure.; Risk factors for basal cell carcinoma include family history.; The diagnosis was made after a skin exam and biopsy.; Surgery is the standard treatment for basal cell carcinoma.; The patient will need regular full skin exams at least once a year to monitor for recurrence.; The patient plans to be extra careful about sun protection.",
         "Basal cell carcinoma (BCC) is the most common type of skin cancer; BCC arises from basal cells in the lower part of the epidermis; BCC most commonly develops in sun-exposed areas such as the face, head, and neck; UV radiation exposure is a primary risk factor for BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Surgery is the most common treatment for BCC; Follow-up includes full skin exams with a doctor at least once a year"
        ],
        [
         "1899",
         "Medical-bf68d23e",
         "Medical",
         "Rewrite the following scenario into a public health advisory: There has been an increase in basal cell carcinoma diagnoses in your community, particularly among older adults with fair skin. Use the clinical guideline to construct an evidence-based advisory focused on prevention, early detection, and high-risk groups.",
         "Public Health Advisory: Increased Basal Cell Carcinoma Cases in Our Community\n\nWe are observing a rise in basal cell carcinoma (BCC), the most common type of skin cancer, especially among older adults with fair skin and light-colored eyes or hair. BCC typically develops in sun-exposed areas such as the face, head, and neck, and risk increases with UV radiation exposure. Individuals with a personal or family history of skin cancer, those who have undergone radiation therapy, or those with immune suppression are at higher risk. We urge the community to practice sun protection, avoid tanning beds, and seek medical evaluation for new or changing skin lesions. Annual full skin exams with your healthcare provider are recommended for early detection and improved outcomes.",
         "Creative Generation",
         "There has been an increase in basal cell carcinoma diagnoses in the community.; The increase is particularly among older adults with fair skin.; Basal cell carcinoma is the most common type of skin cancer.; Basal cell carcinoma typically develops in sun-exposed areas such as the face, head, and neck.; The risk of basal cell carcinoma increases with UV radiation exposure.; Individuals with a personal or family history of skin cancer are at higher risk.; Individuals who have undergone radiation therapy are at higher risk for basal cell carcinoma.; Individuals with immune suppression are at higher risk for basal cell carcinoma.; The community is urged to practice sun protection.; The community is urged to avoid tanning beds.; The community is urged to seek medical evaluation for new or changing skin lesions.; Annual full skin exams with a healthcare provider are recommended for early detection.",
         "Basal cell carcinoma (BCC) is the most common type of skin cancer; BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Fair skin, light hair, and light eye color increase the risk of BCC; Older age is associated with higher risk of BCC; History of skin cancer or family history increases risk of BCC; Radiation therapy and immune suppression are risk factors for BCC; Follow-up includes full skin exams with a doctor at least once a year"
        ],
        [
         "1900",
         "Medical-fd1b07be",
         "Medical",
         "You are a dermatology intern preparing a referral letter to oncology for a patient with recurrent basal cell carcinoma that has spread to lymph nodes. Summarize the clinical findings, risk factors, diagnostic confirmation, and rationale for referral, referencing the guideline.",
         "Referral Letter to Oncology:\n\nDear Colleague,\n\nI am referring a patient with a history of basal cell carcinoma (BCC) who now presents with a recurrence at the original site and clinical evidence of regional lymph node involvement. Clinical findings include a recurrent lesion at the prior excision site and palpable lymphadenopathy. The patient possesses several risk factors for BCC, including fair skin, significant ultraviolet (UV) exposure, and a prior personal history of skin cancer. Diagnostic confirmation was achieved through a combination of thorough medical and family history, physical and skin examination, a confirmatory biopsy of the recurrent lesion, and imaging studies to assess the extent of lymph node involvement. According to NCCN guidelines, recurrence and regional spread of BCC represent a higher-risk scenario that may require multimodal management. The rationale for referral is to evaluate the need for systemic therapy or radiation, as these options are recommended for cases where surgical management alone may be insufficient. Further staging and treatment planning are requested in accordance with current evidence-based guidelines.",
         "Creative Generation",
         "The patient has a history of basal cell carcinoma (BCC).; The patient presents with recurrence at the original site.; The patient has evidence of spread to regional lymph nodes.; The patient has multiple risk factors, including fair skin.; The patient has significant UV exposure.; The patient has a prior history of skin cancer.; The current diagnosis was established via physical and skin examination.; A confirmatory biopsy was performed.; Imaging studies were conducted.; The referral is for expertise regarding systemic therapy or radiation options.; The referral seeks advice on further staging and treatment recommendations.",
         "Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites; Fair skin, light hair, and light eye color increase the risk of BCC; History of skin cancer or family history increases risk of BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Radiation therapy or systemic therapy may be used in some cases of BCC; Treatment options based on risk and recurrence"
        ],
        [
         "1901",
         "Medical-ea29b9d8",
         "Medical",
         "Imagine you are a neuro-oncology fellow. Write a detailed initial diagnostic workup and staging plan for a 62-year-old patient presenting with progressive leg weakness, memory problems, and blurry vision, suspected of having primary CNS lymphoma. Your plan should outline all relevant assessments and justify their use.",
         "For a 62-year-old patient presenting with progressive leg weakness, memory problems, and blurry vision, the initial diagnostic workup for suspected primary CNS lymphoma should include:\n\n1. Neurological examination to assess the extent of neurological deficits and establish a clinical baseline.\n2. MRI of the brain with gadolinium contrast as the most sensitive imaging modality to identify CNS lesions characteristic of lymphoma.\n3. Eye examination using slit lamp and potentially vitrectomy if ocular involvement is suspected, given the blurry vision.\n4. Stereotactic biopsy of the brain lesion to obtain histopathologic confirmation, as this is the standard diagnostic procedure.\n5. Laboratory assessments including complete blood count, comprehensive metabolic panel, lactate dehydrogenase (LDH) levels, and HIV and hepatitis B testing to evaluate for risk factors and baseline organ function.\n6. Lumbar puncture to analyze cerebrospinal fluid for malignant cells, especially given the possibility of CSF involvement in primary CNS lymphoma.\n7. Performance status evaluation to guide further diagnostic and treatment decisions.\nThis comprehensive approach ensures accurate diagnosis, detection of disease extent (including possible eye and CSF involvement), and risk factor assessment to inform treatment planning.",
         "Creative Generation",
         "The patient is 62 years old.; The patient presents with progressive leg weakness.; The patient has memory problems.; The patient experiences blurry vision.; The initial diagnostic workup includes a neurological examination.; The neurological examination assesses the extent of neurological deficits.; An MRI of the brain with gadolinium contrast is included in the workup.; MRI is the most sensitive imaging modality for identifying CNS lesions.; An eye examination using a slit lamp is part of the workup.; Vitrectomy may be performed if ocular involvement is suspected.; A stereotactic biopsy of the brain lesion is necessary for histopathologic confirmation.; Laboratory assessments include complete blood count and comprehensive metabolic panel.; Lactate dehydrogenase (LDH) levels are assessed.; HIV and hepatitis B testing are included in the laboratory assessments.; A lumbar puncture is performed to analyze cerebrospinal fluid for malignant cells.; Performance status evaluation is conducted to guide further decisions.",
         "Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; Eye exam and vitrectomy may be used if the eyes are involved.; Laboratory tests include complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), HIV blood test, and hepatitis B testing.; Lumbar puncture is used to assess for cerebrospinal fluid involvement.; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials."
        ],
        [
         "1902",
         "Medical-c2658ea4",
         "Medical",
         "As a hematologist, develop a comprehensive induction and consolidation treatment plan for a newly diagnosed immunocompetent adult with primary CNS lymphoma confined to the brain. The plan should detail drug regimens, rationale, and supportive care measures.",
         "For an immunocompetent adult with newly diagnosed primary CNS lymphoma confined to the brain, a comprehensive treatment plan includes both induction and consolidation phases, with careful attention to supportive care and multidisciplinary management:\n\nInduction Phase:\n- Initiate high-dose methotrexate-based chemotherapy, which is the cornerstone of induction therapy for primary CNS lymphoma due to its ability to penetrate the blood-brain barrier and effectively target lymphoma cells in the CNS.\n- Add rituximab, a monoclonal antibody targeting CD20, to enhance treatment response, as it is the primary immunotherapy agent used in this setting.\n- Additional agents such as temozolomide or vincristine may be incorporated into the regimen based on established protocols and individual patient tolerance.\n- Corticosteroids (e.g., dexamethasone) should be used as needed to reduce cerebral edema and alleviate neurological symptoms, but should be tapered as soon as feasible to avoid masking disease activity.\n\nConsolidation Phase:\n- After achieving remission or maximal response to induction therapy, proceed to consolidation. The most commonly used approach is whole-brain radiation therapy (WBRT), which aims to eradicate residual disease and reduce the risk of relapse.\n- Alternatively, for selected patients with good performance status, high-dose chemotherapy followed by autologous hematopoietic stem cell rescue may be considered, particularly to minimize long-term neurotoxicity associated with WBRT.\n\nSupportive Care and Monitoring:\n- Throughout all phases, provide comprehensive supportive care to manage treatment-related side effects, prevent infections, and address neurological and cognitive symptoms. This includes regular monitoring of renal function (due to high-dose methotrexate), hydration, leucovorin rescue, and management of cytopenias.\n- Engage a multidisciplinary team—including neurology, oncology, nursing, pharmacy, and supportive services—to optimize patient outcomes and quality of life.\n- Assess performance status regularly to guide treatment intensity and eligibility for clinical trials, which should be considered for all patients given the rarity and complexity of primary CNS lymphoma.\n\nThis approach is consistent with current guidelines and evidence, aiming to maximize disease control while minimizing toxicity and preserving neurological function.",
         "Creative Generation",
         "The patient is an immunocompetent adult.; The patient has newly diagnosed primary CNS lymphoma confined to the brain.; The treatment plan consists of an induction phase.; The induction phase includes high-dose methotrexate-based chemotherapy.; Rituximab is combined with chemotherapy to enhance response.; Temozolomide or vincristine may be added based on protocol and patient tolerance.; Supportive corticosteroids may be used to reduce cerebral edema.; The consolidation phase follows the induction phase.; Consolidation includes whole-brain radiation therapy (WBRT).; High-dose chemotherapy followed by hematopoietic stem cell rescue may be considered.; Supportive care is provided throughout treatment.; A multidisciplinary team is involved in supportive care.; Performance status is monitored regularly.",
         "Treatment options for primary CNS lymphoma include corticosteroids, chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell rescue, and supportive care.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Rituximab is the main immunotherapy drug used for primary CNS lymphoma.; Treatment is typically given in phases: induction and consolidation.; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.; Supportive care is provided to relieve symptoms and side effects at any stage of disease.; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials."
        ],
        [
         "1903",
         "Medical-e6da7d3c",
         "Medical",
         "Rewrite the core recommendations for the diagnosis and management of primary CNS lymphoma into a formal referral letter from a general neurologist to a neuro-oncologist, ensuring all key clinical, diagnostic, and management considerations are included.",
         "Dear Neuro-Oncology Colleague,\n\nI am referring a 58-year-old patient with recent onset progressive arm weakness, confusion, and double vision. MRI with gadolinium contrast revealed a solitary enhancing lesion in the right frontal lobe. The patient has no known history of immunodeficiency but is an older adult. Given these findings, primary CNS lymphoma is strongly suspected.\n\nTo confirm the diagnosis, I recommend proceeding with stereotactic biopsy, as this is the standard diagnostic procedure. Additional workup should include comprehensive laboratory tests (CBC, CMP, LDH, HIV, and hepatitis B), lumbar puncture to assess for cerebrospinal fluid involvement, and detailed eye examination due to reported visual symptoms. Performance status assessment is essential to guide both treatment planning and clinical trial eligibility.\n\nFor management, high-dose methotrexate-based chemotherapy, with consideration for rituximab, should be initiated as induction therapy, followed by consolidation with whole-brain radiation therapy or high-dose chemotherapy with stem cell rescue as appropriate. Supportive care should be provided throughout. I recommend considering clinical trial enrollment if available.\n\nThank you for your expert evaluation and management.",
         "Creative Generation",
         "The patient is 58 years old.; The patient has recent onset progressive arm weakness.; The patient experiences confusion.; The patient has double vision.; MRI with gadolinium contrast revealed a solitary enhancing lesion in the right frontal lobe.; The patient has no known history of immunodeficiency.; Primary CNS lymphoma is strongly suspected.; A stereotactic biopsy is recommended to confirm the diagnosis.; Comprehensive laboratory tests are recommended, including CBC, CMP, LDH, HIV, and hepatitis B.; A lumbar puncture is recommended to assess for cerebrospinal fluid involvement.; A detailed eye examination is necessary due to reported visual symptoms.; Performance status assessment is essential for treatment planning.; High-dose methotrexate-based chemotherapy should be initiated as induction therapy.; Rituximab should be considered for induction therapy.; Consolidation may involve whole-brain radiation therapy or high-dose chemotherapy with stem cell rescue.; Supportive care should be provided throughout treatment.; Clinical trial enrollment should be considered if available.",
         "Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; Laboratory tests include complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), HIV blood test, and hepatitis B testing.; Lumbar puncture is used to assess for cerebrospinal fluid involvement.; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.; Clinical trial participation is recommended for all patients with primary CNS lymphoma."
        ],
        [
         "1904",
         "Medical-96352a3c",
         "Medical",
         "Transform the main points of the guideline into a discharge summary for a patient with primary CNS lymphoma who has completed induction chemotherapy and is entering the consolidation phase.",
         "Discharge Summary\n\nDiagnosis: Primary Central Nervous System Lymphoma (PCNSL)\n\nSummary of Hospital Course: The patient presented with headaches, nausea, and coordination difficulties. MRI with gadolinium contrast revealed multifocal enhancing lesions in the brain, and stereotactic biopsy confirmed the diagnosis of PCNSL. Laboratory evaluation included complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), and HIV testing. Ophthalmologic examination and lumbar puncture were performed, with no evidence of ocular or cerebrospinal fluid (CSF) involvement. The patient's performance status was monitored throughout the hospital course.\n\nTreatment: The patient completed induction chemotherapy consisting of high-dose methotrexate and rituximab, in accordance with current guidelines. Corticosteroids were administered for symptom management. The patient tolerated induction therapy well, with noted improvement in neurological symptoms and no significant complications.\n\nPlan: The patient will now transition to the consolidation phase of treatment, which will include whole-brain radiation therapy (WBRT) as recommended by guidelines. Supportive care measures will continue to address ongoing symptoms and potential side effects of therapy, including counseling, nutritional support, and physical therapy as needed. The patient is encouraged to consider participation in clinical trials, as this is recommended for all patients with PCNSL. Ongoing follow-up will include regular neurological assessments, repeat MRI imaging, blood tests, and performance status evaluations to monitor for disease response and treatment-related effects. Multidisciplinary care will be maintained to optimize quality of life and address any emerging needs.",
         "Creative Generation",
         "The patient has primary central nervous system lymphoma (PCNSL).; The patient presented with headaches, nausea, and coordination difficulties.; MRI with gadolinium contrast demonstrated multifocal enhancing lesions in the brain.; Stereotactic biopsy confirmed the diagnosis of PCNSL.; Laboratory evaluation included CBC, CMP, LDH, and HIV testing.; An eye examination showed no evidence of ocular involvement.; A lumbar puncture showed no evidence of cerebrospinal fluid involvement.; Performance status was assessed throughout the hospital course.; The patient completed induction chemotherapy with high-dose methotrexate and rituximab.; Corticosteroids were used for symptom management.; The patient tolerated therapy well.; The patient showed improvement in neurological symptoms.; The patient will transition to consolidation therapy with whole-brain radiation therapy (WBRT).; Supportive care will continue to address ongoing symptoms.; The patient is encouraged to consider clinical trial participation.; Regular follow-up will include repeat MRI, blood tests, and performance status assessments.",
         "Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; Treatment is typically given in phases: induction and consolidation.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Rituximab is the main immunotherapy drug used for primary CNS lymphoma.; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.; Supportive care is provided to relieve symptoms and side effects at any stage of disease.; Follow-up/Surveillance: Repeat MRI, eye exam, blood tests, performance status assessment.; Clinical trial participation is recommended for all patients with primary CNS lymphoma."
        ],
        [
         "1905",
         "Medical-3396b459",
         "Medical",
         "Write a public health advisory summarizing risk factors, key symptoms, and the importance of early specialist referral for primary CNS lymphoma, using evidence from the guideline.",
         "Public Health Advisory: Primary Central Nervous System Lymphoma (PCNSL)\n\nPrimary CNS lymphoma is a rare but aggressive cancer that originates from lymphocytes within the central nervous system, most commonly affecting the brain but also the spinal cord, cerebrospinal fluid, and eyes. Individuals at increased risk include those with impaired immune systems, such as patients with immunodeficiency disorders, HIV infection, Epstein-Barr virus, autoimmune diseases, organ transplants, and older adults.\n\nKey symptoms to watch for include leg or arm weakness, difficulties with coordination or movement, changes in personality or behavior, memory problems, headaches, nausea, vomiting, seizures, and vision changes such as blurry or double vision. Early and accurate diagnosis is critical for improving outcomes. Diagnostic evaluation includes neurological examination, MRI with gadolinium contrast, stereotactic biopsy, laboratory tests, eye examination, and lumbar puncture.\n\nPrompt referral to a neuro-oncology specialist is essential for timely diagnosis and initiation of evidence-based therapy, which typically involves high-dose methotrexate-based chemotherapy and possible whole-brain radiation therapy. Participation in clinical trials and supportive care are also recommended. Early detection and specialist management can significantly impact patient prognosis.",
         "Creative Generation",
         "Primary CNS lymphoma is a rare but aggressive cancer.; Primary CNS lymphoma originates from lymphocytes within the central nervous system.; It most commonly affects the brain.; Primary CNS lymphoma can also affect the spinal cord, cerebrospinal fluid, and eyes.; Individuals at increased risk include those with impaired immune systems.; Risk factors include immunodeficiency disorders, HIV infection, and Epstein-Barr virus.; Autoimmune diseases and organ transplants are also risk factors.; Older adults are at increased risk for primary CNS lymphoma.; Key symptoms include leg or arm weakness.; Other symptoms include difficulties with coordination or movement.; Changes in personality or behavior can occur.; Memory problems are a symptom of primary CNS lymphoma.; Headaches, nausea, vomiting, seizures, and vision changes are also symptoms.; Early and accurate diagnosis is critical for improving outcomes.; Diagnostic evaluation includes neurological examination and MRI with gadolinium contrast.; Stereotactic biopsy is part of the diagnostic evaluation.; Laboratory tests, eye examination, and lumbar puncture are included in the evaluation.; Prompt referral to a neuro-oncology specialist is essential for timely diagnosis.; Evidence-based therapy typically involves high-dose methotrexate-based chemotherapy.; Whole-brain radiation therapy may also be part of the treatment.; Participation in clinical trials and supportive care are recommended.",
         "Primary CNS lymphoma is a rare and aggressive cancer that starts in lymphocytes within the central nervous system.; Primary CNS lymphoma most commonly affects the brain, but can also involve the spinal cord, cerebrospinal fluid, and eyes.; Impaired immune system is a risk factor for primary CNS lymphoma.; Immunodeficiency disorders, HIV infection, Epstein-Barr virus, autoimmune diseases, organ transplant, and older age are risk factors for primary CNS lymphoma.; Primary CNS lymphoma can cause neurological symptoms such as leg or arm weakness, coordination or movement difficulties, personality or behavior changes, depression, confusion, memory problems, incontinence, difficulty speaking or swallowing, headaches, nausea, vomiting, seizures, and vision changes.; Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Clinical trial participation is recommended for all patients with primary CNS lymphoma."
        ],
        [
         "1906",
         "Medical-beb1f30e",
         "Medical",
         "Imagine you are a dermatology attending preparing a referral letter for a patient with a newly diagnosed high-risk cutaneous squamous cell carcinoma (CSCC) on the scalp. Summarize the case, risk assessment, diagnostic findings, and recommend next steps, incorporating relevant guideline recommendations.",
         "Dear Colleague,\n\nI am referring a 68-year-old fair-skinned male recently diagnosed with high-risk cutaneous squamous cell carcinoma (CSCC) of the scalp. The patient has a history of chronic sun exposure and presented with a 2.5 cm solid, irregular lesion on an area of chronic scarring. Clinical examination and excision biopsy confirmed invasive CSCC with perineural invasion and poorly defined borders. Imaging (CT) did not reveal nodal or distant metastasis. Risk assessment classified the tumor as high-risk due to its size, location (scalp), perineural invasion, and history of recurrence. \n\nGuidelines recommend Mohs surgery/PDEMA as the preferred treatment for high-risk local CSCC, with consideration of adjuvant radiation therapy if surgical margins are inadequate or perineural invasion is extensive. Regular skin and lymph node exams every 3-6 months for the first 2 years are advised for surveillance. Please see attached pathology and imaging reports for further details.\n\nSincerely,\nDermatology Attending",
         "Creative Generation",
         "The patient is a 68-year-old fair-skinned male.; The patient has been diagnosed with high-risk cutaneous squamous cell carcinoma (CSCC) of the scalp.; The patient has a history of chronic sun exposure.; The patient presented with a 2.5 cm solid, irregular lesion on an area of chronic scarring.; Clinical examination confirmed invasive CSCC with perineural invasion.; The tumor has poorly defined borders.; Imaging (CT) did not reveal nodal or distant metastasis.; Risk assessment classified the tumor as high-risk due to its size and location.; Mohs surgery/PDEMA is the preferred treatment for high-risk local CSCC.; Adjuvant radiation therapy may be considered if surgical margins are inadequate.; Regular skin and lymph node exams every 3-6 months for the first 2 years are advised.",
         "High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible.; Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status.; CSCC most commonly arises in sun-exposed areas, especially in fair-skinned individuals.; Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected.; Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage."
        ],
        [
         "1907",
         "Medical-9e9cc51b",
         "Medical",
         "You are an oncology nurse tasked with drafting a patient-friendly discharge summary for a person with regional CSCC (lymph node involvement) who has completed surgery and adjuvant radiation. Use the guideline to summarize their diagnosis, treatment, risk factors, and follow-up plan.",
         "Discharge Summary for Regional Cutaneous Squamous Cell Carcinoma (CSCC)\n\nDiagnosis: You have been diagnosed with cutaneous squamous cell carcinoma (CSCC) that had spread to a nearby lymph node, which is known as regional CSCC. Major risk factors for this type of skin cancer include chronic sun exposure and a weakened immune system.\n\nTreatment: Your treatment included surgery to remove both the skin tumor and the affected lymph node(s). After surgery, you received radiation therapy to the area to help lower the risk of the cancer coming back. Imaging tests after treatment did not show any further spread of the cancer.\n\nRisk Factors: The main risk factors for CSCC are long-term sun exposure, a weakened immune system, and a history of chronic wounds or scarring. These factors can increase the chance of developing skin cancer or having it return.\n\nFollow-up Plan: Regular follow-up is important to monitor for any signs of recurrence. You will have skin and lymph node checks every 2–3 months during the first year after treatment, then every 2–4 months in the second year, and less frequently in the following years. Imaging may be used as part of your ongoing surveillance. Please continue to protect your skin from the sun and promptly report any new or changing skin lesions to your care team.\n\nThank you for your cooperation and commitment to your follow-up care.",
         "Creative Generation",
         "The patient has regional cutaneous squamous cell carcinoma (CSCC) with lymph node involvement.; Major risk factors include chronic sun exposure and a weakened immune system.; The patient underwent surgery to remove the skin tumor and the affected lymph node.; The patient received radiation therapy to reduce the risk of recurrence.; No evidence of further spread was found on imaging.; Follow-up will include skin and lymph node checks every 2–3 months in the first year.; Follow-up will include checks every 2–4 months in the second year.; Follow-up will be less frequent after the second year.; Imaging will be used for ongoing surveillance.; The patient is advised to continue sun protection.; The patient should report any new skin changes promptly.",
         "Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy.; Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars.; Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage.; Imaging is used for staging and surveillance in regional and high-risk cases.; Skin and lymph node exams every 2-3 months for 1 year, every 2-4 months for year 2, every 4-6 months for 3 years, then every 6-12 months."
        ],
        [
         "1908",
         "Medical-970792d6",
         "Medical",
         "Assume the role of a medical intern on the dermatology service. You are asked to write a SOAP progress note for a patient with actinic keratosis and a history of immunosuppression, referencing both diagnosis and management per guidelines.",
         "SOAP Note\n\nSubjective: Patient reports several rough, scaly patches on sun-exposed areas of the face and forearms. Denies pain or bleeding. Notable history includes chronic immunosuppression following organ transplantation, which increases the risk for skin malignancies.\n\nObjective: Physical examination reveals multiple erythematous, scaly papules on the left cheek and dorsal hands, consistent with actinic keratoses. No palpable lymphadenopathy is present. Skin biopsy confirms the diagnosis of actinic keratosis. No evidence of invasive disease at this time.\n\nAssessment: Actinic keratosis in a patient with chronic immunosuppression. Immunosuppressed individuals are at significantly increased risk for progression of actinic keratosis to cutaneous squamous cell carcinoma (CSCC), as well as for developing additional lesions.\n\nPlan: Initiate cryotherapy for discrete, visible lesions and prescribe topical 5-fluorouracil for field treatment of affected areas, in accordance with current guidelines. Provide education on strict photoprotection, including use of broad-spectrum sunscreen, protective clothing, and avoidance of peak sun exposure. Emphasize the importance of regular self-skin examinations and schedule dermatologic follow-up every 3–6 months for comprehensive skin and lymph node exams, given the elevated risk of progression to CSCC. Advise prompt evaluation of any new, changing, or symptomatic lesions.",
         "Creative Generation",
         "The patient has actinic keratosis.; The patient has a history of immunosuppression due to organ transplant.; The patient reports several rough, scaly patches on sun-exposed areas of the face and forearms.; The patient reports no pain or bleeding.; The examination reveals multiple erythematous, scaly papules on the left cheek and dorsal hands.; There is no palpable lymphadenopathy.; A biopsy confirms the diagnosis of actinic keratosis.; The assessment indicates an increased risk for progression to cutaneous squamous cell carcinoma (CSCC).; Cryotherapy will be initiated for visible lesions.; Topical 5-fluorouracil will be used for field treatment.; The patient will be educated on strict photoprotection.; Regular skin exams will be scheduled every 3–6 months due to increased risk.; The patient will be monitored for any new or changing lesions.",
         "Actinic keratosis is a precancerous lesion that can progress to CSCC.; Photodynamic therapy, cryotherapy, and topical therapies (5-fluorouracil, imiquimod, tirbanibulin) are used for actinic keratoses and superficial CSCC.; Major risk factors for CSCC include chronic sun exposure, actinic keratosis, genetic syndromes, weakened immune system, and chronic wounds or scars.; Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage.; Immunosuppression is a risk factor for both actinic keratosis and progression to CSCC."
        ],
        [
         "1909",
         "Medical-5b2de94d",
         "Medical",
         "You are a public health official drafting an advisory for primary care providers about prevention, early detection, and high-risk populations for cutaneous squamous cell carcinoma (CSCC). Use guideline facts to inform your advisory.",
         "Public Health Advisory: Prevention and Early Detection of Cutaneous Squamous Cell Carcinoma (CSCC)\n\nPrimary care providers should be vigilant for CSCC, the second most common skin cancer, particularly in fair-skinned individuals and those with extensive sun exposure. High-risk populations include patients with chronic sun exposure, indoor tanning history, actinic keratosis, genetic syndromes (e.g., xeroderma pigmentosum, RDEB), immunosuppression, and chronic wounds or scars. \n\nEarly detection relies on clinical examination for scaly patches or misshapen skin lesions, especially in sun-exposed or chronically damaged areas. Biopsy is essential for suspicious lesions. Encourage sun protection and routine skin exams, especially for high-risk patients. Prompt referral for dermatologic evaluation is recommended for new, persistent, or changing lesions.\n",
         "Creative Generation",
         "CSCC is the second most common skin cancer.; Primary care providers should be vigilant for CSCC.; Fair-skinned individuals are at higher risk for CSCC.; Individuals with extensive sun exposure are at higher risk for CSCC.; High-risk populations include patients with chronic sun exposure.; Indoor tanning history is a risk factor for CSCC.; Actinic keratosis is a precursor to CSCC.; Genetic syndromes such as xeroderma pigmentosum increase risk for CSCC.; Immunosuppression is a risk factor for CSCC.; Chronic wounds or scars are associated with increased risk for CSCC.; Early detection relies on clinical examination for scaly patches or misshapen skin lesions.; Biopsy is essential for suspicious lesions.; Sun protection and routine skin exams are encouraged for high-risk patients.; Prompt referral for dermatologic evaluation is recommended for new, persistent, or changing lesions.",
         "Squamous cell skin cancer (CSCC) is the second most common type of skin cancer.; CSCC most commonly arises in sun-exposed areas, especially in fair-skinned individuals.; Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars.; Symptoms of CSCC include scaly patches, solid or misshapen skin lesions, and lesions in areas of chronic damage.; Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected."
        ],
        [
         "1910",
         "Medical-22918f14",
         "Medical",
         "Imagine you are a hematology fellow receiving a new referral for a patient with suspected chronic myeloid leukemia (CML). Draft a detailed diagnostic workup plan, including key laboratory and molecular studies, and explain how you would confirm the diagnosis and characterize the disease phase.",
         "For a patient with suspected chronic myeloid leukemia (CML), the diagnostic workup should be comprehensive and systematic. I would begin with a detailed medical history and physical examination, including assessment for symptoms such as fatigue, weight loss, night sweats, and splenomegaly. Laboratory evaluation would start with a complete blood count (CBC) with differential to identify leukocytosis, particularly increased granulocytes, and to assess platelet and red blood cell levels. A peripheral blood smear would be performed to evaluate the spectrum of granulocyte maturation and to detect any abnormal or immature cells. Bone marrow aspiration and biopsy would be considered to assess cellularity, myeloid proliferation, and the percentage of blasts, which is critical for distinguishing between chronic, accelerated, and blast phases of CML. Cytogenetic analysis (karyotyping) would be performed to detect the Philadelphia chromosome (Ph), resulting from the t(9;22)(q34;q11) translocation. Fluorescence in situ hybridization (FISH) or reverse transcriptase polymerase chain reaction (RT-PCR) would be used to confirm the presence of the BCR::ABL1 fusion gene, which is required for a definitive diagnosis. The disease phase is characterized by the proportion of blasts in blood or marrow: chronic phase (<10% blasts), accelerated phase (10–19% blasts), or blast phase (≥20% blasts). This integrated approach confirms the diagnosis, distinguishes CML from other myeloproliferative neoplasms, and guides subsequent management.",
         "Creative Generation",
         "The diagnostic workup for suspected chronic myeloid leukemia (CML) begins with a complete blood count (CBC).; The CBC assesses for increased white blood cell (WBC) counts, particularly granulocytes.; The CBC evaluates platelet (PLT) and red blood cell (RBC) levels.; A peripheral blood smear is ordered to characterize granulocyte lineage.; The peripheral blood smear helps identify abnormal cells.; A bone marrow aspiration and biopsy are requested to assess myeloid progenitor cell proliferation.; The bone marrow evaluation looks for any increase in blasts.; An increase in blasts could indicate blast phase CML (BP-CML).; Cytogenetic analysis is performed to detect the presence of the Philadelphia chromosome (Ph).; The Philadelphia chromosome is the abnormal chromosome 22 resulting from the translocation between chromosomes 9 and 22.; Molecular testing for the BCR::ABL1 fusion gene is conducted.; The presence of the BCR::ABL1 fusion gene is required for a definitive diagnosis of CML.; The combination of clinical, morphologic, cytogenetic, and molecular findings confirms CML.; The findings help differentiate CML from other myeloproliferative neoplasms.; The findings determine if the disease is in chronic or blast phase.",
         "CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.; Blood tests and bone marrow tests are used to diagnose CML.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; Blast phase CML (BP-CML) is an advanced form of CML with increased blasts."
        ],
        [
         "1911",
         "Medical-c5176f5c",
         "Medical",
         "You are an oncologist preparing a treatment initiation summary for a patient newly diagnosed with chronic phase CML. Summarize the pathogenesis, diagnostic criteria, and first-line therapeutic strategy, referencing relevant biomarkers and molecular targets.",
         "Chronic myeloid leukemia (CML) is a blood cancer caused by the BCR::ABL1 fusion gene, which arises from a translocation between chromosomes 9 and 22, forming the Philadelphia chromosome (Ph). Diagnosis is established by detecting either the Ph chromosome or the BCR::ABL1 fusion gene, typically via cytogenetic and molecular testing of blood or bone marrow samples. The disease originates in blood stem cells, leading to excessive production of myeloid progenitor cells and increased granulocyte (white blood cell) counts, often accompanied by abnormal platelet levels. The primary therapeutic approach targets the BCR::ABL1 protein, whose abnormal tyrosine kinase activity drives disease progression. Initiation of treatment with a BCR::ABL1 protein inhibitor is recommended as first-line therapy for chronic phase CML, with ongoing monitoring of molecular response.",
         "Creative Generation",
         "Chronic myeloid leukemia (CML) is caused by the BCR::ABL1 fusion gene.; The BCR::ABL1 fusion gene arises from a translocation between chromosomes 9 and 22.; The translocation forms the Philadelphia chromosome (Ph).; Diagnosis of CML is established by detecting the Ph chromosome or the BCR::ABL1 fusion gene.; Detection is typically done via cytogenetic and molecular testing of blood or bone marrow samples.; CML originates in blood stem cells.; CML leads to excessive production of myeloid progenitor cells.; CML is associated with increased granulocyte (white blood cell) counts.; CML is often accompanied by abnormal platelet levels.; The primary therapeutic approach targets the BCR::ABL1 protein.; The BCR::ABL1 protein has abnormal tyrosine kinase activity.; The abnormal tyrosine kinase activity drives disease progression.; Initiation of treatment with a BCR::ABL1 protein inhibitor is recommended as first-line therapy for chronic phase CML.; Ongoing monitoring of molecular response is necessary.",
         "Chronic myeloid leukemia (CML) is a type of blood cancer.; CML is caused by the BCR::ABL1 fusion gene.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Treatment for CML aims to inhibit BCR::ABL1 protein activity."
        ],
        [
         "1912",
         "Medical-3aed2370",
         "Medical",
         "Transform the core clinical facts about chronic myeloid leukemia (CML) into a structured discharge summary for a patient completing diagnostic evaluation and beginning therapy.",
         "**Discharge Summary**\n\nDiagnosis: Chronic Myeloid Leukemia (CML)\n\nSummary of Hospital Course:\nThe patient underwent evaluation for persistent leukocytosis and abnormal platelet counts identified on routine laboratory testing. Further assessment included blood and bone marrow analyses, which demonstrated marked proliferation of granulocytes and myeloid progenitor cells. Cytogenetic testing revealed the presence of the Philadelphia chromosome (Ph), resulting from a translocation between chromosomes 9 and 22. Molecular studies confirmed the BCR::ABL1 fusion gene, establishing the diagnosis of CML. The disease is currently classified as being in the chronic phase, with no evidence of accelerated or blast phase transformation.\n\nKey Diagnostic Findings:\n- Hematology: Elevated white blood cell count (predominantly granulocytes) and abnormal platelet counts\n- Bone Marrow: Hypercellularity with increased myeloid progenitor cells\n- Cytogenetics: Philadelphia chromosome (t(9;22)(q34;q11)) detected\n- Molecular: BCR::ABL1 fusion gene present\n\nManagement Plan:\n- Initiate BCR::ABL1 tyrosine kinase inhibitor therapy as first-line treatment\n- Arrange for regular monitoring of complete blood counts and molecular response (BCR::ABL1 transcript levels)\n- Provide education on disease process, treatment expectations, and the importance of adherence and follow-up\n- Encourage the patient to maintain organized medical records and communicate any new symptoms promptly\n- Recommend ongoing support from family, caregivers, and the healthcare team\n\nThe patient and family have been counseled regarding the diagnosis, treatment plan, and the need for close follow-up with the hematology/oncology team.",
         "Creative Generation",
         "The diagnosis is chronic myeloid leukemia (CML).; The patient was evaluated for elevated white blood cell counts.; The patient had abnormal platelet counts.; Blood analyses revealed increased granulocytes.; Bone marrow analyses revealed increased myeloid progenitor cells.; Cytogenetic studies confirmed the presence of the Philadelphia chromosome (Ph).; The Philadelphia chromosome results from a translocation between chromosome 9 and 22.; Molecular studies confirmed the presence of the BCR::ABL1 fusion gene.; The findings fulfill diagnostic criteria for CML.; The disease is currently in the chronic phase.; Initiation of BCR::ABL1 protein inhibitor therapy is planned.; Ongoing monitoring of blood counts and molecular response will occur.",
         "CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Blood tests and bone marrow tests are used to diagnose CML.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; Treatment for CML aims to inhibit BCR::ABL1 protein activity."
        ],
        [
         "1913",
         "Medical-fbacfb98",
         "Medical",
         "Reframe the guideline information into a referral note addressed to a specialist, clearly stating the clinical suspicion, supporting laboratory findings, and rationale for specialist input.",
         "Dear Hematology Specialist,\n\nI am referring a patient with clinical and laboratory findings suggestive of chronic myeloid leukemia (CML). The patient presents with persistent leukocytosis, notably increased granulocytes, and abnormal platelet counts identified on routine blood tests. Bone marrow evaluation demonstrated hypercellularity with expansion of myeloid progenitor cells. Cytogenetic analysis revealed the Philadelphia chromosome (Ph), resulting from a translocation between chromosomes 9 and 22. Molecular studies confirmed the presence of the BCR::ABL1 fusion gene. Given these findings, CML is strongly suspected and I am seeking your expertise for confirmation of diagnosis, disease phase classification, and initiation of targeted therapy.",
         "Creative Generation",
         "The patient is being referred for suspected chronic myeloid leukemia (CML).; The patient presents with persistent leukocytosis.; The patient has notably increased granulocytes.; The patient has abnormal platelet counts identified on routine blood tests.; Bone marrow evaluation demonstrated hypercellularity.; The hypercellularity indicates expansion of myeloid progenitor cells.; Cytogenetic analysis revealed the Philadelphia chromosome (Ph).; The Philadelphia chromosome results from a translocation between chromosomes 9 and 22.; Molecular studies confirmed the presence of the BCR::ABL1 fusion gene.; CML is strongly suspected based on these findings.; The referral seeks confirmation of diagnosis.; The referral seeks disease phase classification.; The referral seeks initiation of targeted therapy.",
         "CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Blood tests and bone marrow tests are used to diagnose CML.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis."
        ],
        [
         "1914",
         "Medical-70301a25",
         "Medical",
         "You are a public health officer tasked with writing an educational advisory on the importance of genetic and molecular testing in diagnosing chronic myeloid leukemia (CML). Summarize the key genetic mechanisms, diagnostic requirements, and implications for treatment.",
         "**Public Health Advisory: The Role of Genetic and Molecular Testing in CML Diagnosis**\n\nChronic myeloid leukemia (CML) is a blood cancer defined by a specific genetic alteration: the BCR::ABL1 fusion gene, formed by a translocation between chromosomes 9 and 22, leading to the formation of the Philadelphia chromosome (Ph). Accurate diagnosis requires laboratory confirmation of either the Ph chromosome or the BCR::ABL1 fusion gene through cytogenetic and molecular testing of blood or bone marrow samples. These tests distinguish CML from other blood disorders and are critical for selecting appropriate therapy. Targeted treatments that inhibit the BCR::ABL1 protein have dramatically improved outcomes. Public health initiatives should ensure access to advanced molecular diagnostics for all suspected CML patients.",
         "Creative Generation",
         "Chronic myeloid leukemia (CML) is defined by the BCR::ABL1 fusion gene.; The BCR::ABL1 fusion gene is formed by a translocation between chromosomes 9 and 22.; The translocation leads to the formation of the Philadelphia chromosome (Ph).; Accurate diagnosis of CML requires laboratory confirmation of the Ph chromosome or the BCR::ABL1 fusion gene.; Laboratory confirmation is done through cytogenetic and molecular testing of blood or bone marrow samples.; These tests distinguish CML from other blood disorders.; The tests are critical for selecting appropriate therapy.; Targeted treatments that inhibit the BCR::ABL1 protein have improved outcomes.; Public health initiatives should ensure access to advanced molecular diagnostics for suspected CML patients.",
         "CML is caused by the BCR::ABL1 fusion gene.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; Blood tests and bone marrow tests are used to diagnose CML.; Treatment for CML aims to inhibit BCR::ABL1 protein activity."
        ],
        [
         "1915",
         "Medical-0f84be73",
         "Medical",
         "As a pulmonologist, you are seeing a 62-year-old patient with a 40 pack-year smoking history who presents with a persistent cough. Imaging has revealed a solitary lung nodule. Using the clinical practice guidelines provided, draft a detailed diagnostic and initial management plan, including risk assessment, confirmatory steps, and early treatment considerations.",
         "This 62-year-old patient with a 40 pack-year smoking history and a persistent cough is at high risk for lung cancer, as tobacco use is the most significant risk factor. The discovery of a solitary lung nodule on imaging requires a structured diagnostic approach. First, a comprehensive risk assessment should be performed, considering the patient's age, smoking history, and nodule characteristics. Multidisciplinary evaluation by a pulmonologist, thoracic radiologist, and thoracic surgeon is recommended. Further imaging, such as a high-resolution CT scan, may be obtained to better characterize the nodule and assess for additional lesions or lymphadenopathy. If the nodule is suspicious for malignancy, a tissue diagnosis via biopsy (e.g., CT-guided, bronchoscopic, or surgical) is essential to confirm cancer and determine the histologic subtype, most commonly non-small cell lung cancer (NSCLC). Staging investigations, including PET-CT and brain imaging if indicated, should be performed to assess for local or distant spread. For early-stage NSCLC, surgical resection is the preferred treatment, with radiation therapy as an alternative for patients who are not surgical candidates. In cases of locally advanced disease, a combination of chemotherapy and radiation, and possibly surgery, may be considered. Throughout the process, supportive care should address symptoms such as cough and chest pain, and a plan for post-treatment surveillance should be established to monitor for recurrence.",
         "Creative Generation",
         "The patient has a significant tobacco smoking history.; The patient is at high risk for lung cancer.; A solitary lung nodule was detected on imaging.; A biopsy is recommended to confirm malignancy.; The biopsy is essential for diagnosis.; If the biopsy confirms non-small cell lung cancer (NSCLC), the subtype will be determined.; The likely subtypes of NSCLC include adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.; The disease will be staged after biopsy confirmation.; For early-stage (Stage 1) NSCLC, surgery is the primary treatment.; Radiation therapy may be an option in some cases for early-stage NSCLC.; If the disease is locally advanced (Stage 2 or 3), chemoradiation and possibly surgery would be considered.; Supportive care should be integrated to address symptoms such as cough and chest pain.; Follow-up care with surveillance will be planned after initial treatment.",
         "Tobacco smoking is the biggest risk factor for lung cancer.; Lung nodules may be detected by imaging and require further assessment to determine malignancy.; Biopsy is used to confirm lung cancer diagnosis.; NSCLC is the most common type of lung cancer.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; Radiation therapy is used for some early NSCLC cases.; Chemoradiation is used for some locally advanced NSCLC cases.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Follow-up care is planned after treatment and includes surveillance for recurrence."
        ],
        [
         "1916",
         "Medical-6e3f025e",
         "Medical",
         "You are a medical intern tasked with writing a referral note for a patient with suspected Stage 2 NSCLC based on the guideline. Your note should summarize the diagnostic findings, risk factors, and recommend further specialist evaluation and treatment options.",
         "Referral Note:\n\nThe patient is a 58-year-old individual with a significant 30 pack-year history of tobacco use, presenting with persistent cough and chest pain. Diagnostic imaging identified a lung nodule, and subsequent biopsy confirmed the diagnosis of non-small cell lung cancer (NSCLC). Staging workup suggests likely Stage 2 disease, characterized by local extension of the tumor without evidence of distant metastasis. Notable risk factors include chronic tobacco exposure and possible occupational exposure to asbestos, both of which are established contributors to lung cancer risk.\n\nGiven the diagnosis and staging, referral to a thoracic oncology specialist is recommended for comprehensive evaluation and definitive management planning. According to current guidelines, treatment options for Stage 2 NSCLC include surgical resection when feasible, and/or chemoradiation, depending on the patient's overall health status and tumor characteristics. Multidisciplinary discussion is advised to tailor the treatment approach. Supportive care should be initiated to address symptoms and optimize quality of life, and a structured follow-up plan for surveillance of recurrence or progression should be established.",
         "Creative Generation",
         "The patient is a 58-year-old with a 30 pack-year smoking history.; The patient presents with persistent cough and chest pain.; Imaging revealed a lung nodule.; A biopsy confirmed non-small cell lung cancer (NSCLC).; The NSCLC is likely Stage 2 based on local extension without distant spread.; Major risk factors include tobacco use.; Possible occupational exposure to asbestos is also a risk factor.; A thoracic oncology evaluation is recommended for definitive staging and management.; Treatment options include surgery and/or chemoradiation.; Supportive care for symptom management should be discussed.; Follow-up surveillance should be planned.",
         "Stage 2 and Stage 3 NSCLC are considered locally advanced.; Biopsy is used to confirm lung cancer diagnosis.; Imaging is used to detect lung nodules.; Tobacco smoking is the biggest risk factor for lung cancer.; Exposure to asbestos increases lung cancer risk.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; Chemoradiation is used for some locally advanced NSCLC cases.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Follow-up care is planned after treatment and includes surveillance for recurrence."
        ],
        [
         "1917",
         "Medical-8c4b4b2f",
         "Medical",
         "Rewrite the clinical practice guideline content into a patient-friendly discharge summary for a person who has undergone surgery for Stage 1 NSCLC. The summary should explain the diagnosis, risk factors, treatment performed, and follow-up plan.",
         "Discharge Summary:\n\nDiagnosis: Early-stage non-small cell lung cancer (NSCLC), specifically Stage 1, was confirmed after your recent surgery. This cancer type most often develops in people with risk factors like tobacco smoking and exposure to substances such as asbestos or air pollution. You underwent successful surgical removal of the tumor, which is the standard treatment for early NSCLC. No evidence of spread was found at this stage. Moving forward, you will have regular follow-up visits and imaging to monitor for recurrence. Please report any new symptoms such as cough or chest pain promptly.",
         "Creative Generation",
         "The diagnosis is early-stage non-small cell lung cancer (NSCLC), specifically Stage 1.; The diagnosis was confirmed after recent surgery.; Early-stage NSCLC most often develops in people with risk factors like tobacco smoking.; Exposure to substances such as asbestos or air pollution is also a risk factor.; The patient underwent successful surgical removal of the tumor.; Surgical removal is the standard treatment for early NSCLC.; No evidence of spread was found at this stage.; Regular follow-up visits and imaging will be conducted to monitor for recurrence.; The patient should report any new symptoms such as cough or chest pain promptly.",
         "Stage 1 NSCLC is considered early stage.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; NSCLC is the most common type of lung cancer.; Tobacco smoking is the biggest risk factor for lung cancer.; Exposure to asbestos and air pollution are risk factors for lung cancer.; Follow-up care is planned after treatment and includes surveillance for recurrence.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms."
        ],
        [
         "1918",
         "Medical-d5964ccf",
         "Medical",
         "As a public health officer, draft a community health advisory on lung cancer prevention and early detection, integrating key guideline facts on risk factors, screening, and symptom awareness.",
         "Community Health Advisory: Preventing and Detecting Lung Cancer Early\n\nLung cancer is a leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) being the most common type. The primary risk factor for lung cancer is tobacco smoking, but exposure to secondhand smoke, radon, asbestos, air pollution, and certain occupational hazards (such as diesel fumes) also increase risk. While anyone can develop lung cancer, individuals with a history of heavy smoking or significant exposure to these risk factors are at higher risk and should discuss lung cancer screening with their healthcare provider. Screening, such as low-dose CT scans, is recommended for those at high risk and can detect lung cancer at an early, more treatable stage—often before symptoms appear. Early symptoms may include a persistent cough, chest pain, shortness of breath, or unexplained weight loss. Quitting smoking and minimizing exposure to harmful substances are the most effective ways to reduce your risk. Regular checkups, updating your healthcare provider on your family and exposure history, and being aware of new or persistent respiratory symptoms are important for early detection. Participation in clinical trials and supportive care services may also improve outcomes for those diagnosed with lung cancer.",
         "Creative Generation",
         "Lung cancer is a leading cause of cancer-related deaths.; The most common type of lung cancer is non-small cell lung cancer (NSCLC).; NSCLC is strongly linked to tobacco smoking.; Exposure to substances like radon, asbestos, and air pollution is also a risk factor for lung cancer.; Individuals with a history of heavy smoking should ask their healthcare provider about lung cancer screening.; Lung cancer screening can detect cancer at an early, more treatable stage.; Warning signs of lung cancer include persistent cough and chest pain.; Quitting smoking significantly lowers the risk of lung cancer.; Reducing exposure to harmful substances also lowers the risk.; Regular follow-up and participation in clinical trials may improve outcomes.",
         "NSCLC is the most common type of lung cancer.; Tobacco smoking is the biggest risk factor for lung cancer.; Exposure to radon, asbestos, and air pollution are risk factors for lung cancer.; Lung cancer screening is recommended for people at high risk.; Lung cancer screening aims to detect cancer at an early, more treatable stage.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Clinical trials are available for lung cancer treatment and prevention.; Supportive care extends and enhances life for people with lung cancer."
        ],
        [
         "1919",
         "Medical-0ec610fa",
         "Medical",
         "Format the key elements of NSCLC diagnosis and management from the guideline into a SOAP (Subjective, Objective, Assessment, Plan) note for a new oncology consultation.",
         "SOAP Note:\n\nSubjective: Patient reports persistent cough and intermittent chest pain. History includes current tobacco smoking and prior exposure to diesel fumes.\n\nObjective: Imaging revealed a lung nodule; biopsy confirmed NSCLC. No evidence of distant spread on staging.\n\nAssessment: Newly diagnosed NSCLC, likely early or locally advanced stage. Significant risk factors include tobacco use and occupational exposure.\n\nPlan: Refer for surgical evaluation (if early stage), consider chemoradiation for locally advanced disease. Initiate supportive care for symptom management. Enroll in follow-up care and surveillance after primary treatment. Discuss potential clinical trial participation.",
         "Creative Generation",
         "The patient reports persistent cough and intermittent chest pain.; The patient has a history of current tobacco smoking.; The patient has prior exposure to diesel fumes.; Imaging revealed a lung nodule.; A biopsy confirmed non-small cell lung cancer (NSCLC).; There is no evidence of distant spread on staging.; The assessment indicates newly diagnosed NSCLC, likely early or locally advanced stage.; Significant risk factors include tobacco use and occupational exposure.; A referral for surgical evaluation is planned if the disease is early stage.; Chemoradiation will be considered for locally advanced disease.; Supportive care for symptom management will be initiated.; Follow-up care and surveillance after primary treatment will be enrolled.; Potential clinical trial participation will be discussed.",
         "Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Lung nodules may be detected by imaging and require further assessment to determine malignancy.; Biopsy is used to confirm lung cancer diagnosis.; NSCLC is the most common type of lung cancer.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; Chemoradiation is used for some locally advanced NSCLC cases.; Tobacco smoking and exposure to diesel fumes are risk factors for lung cancer.; Follow-up care is planned after treatment and includes surveillance for recurrence.; Clinical trials are available for lung cancer treatment and prevention.; Supportive care extends and enhances life for people with lung cancer."
        ],
        [
         "1920",
         "Medical-65be7ca5",
         "Medical",
         "Imagine you are a head and neck cancer specialist preparing a referral letter for a 45-year-old male from Southeast Asia with suspected nasopharyngeal carcinoma (NPC). Summarize the relevant risk factors, preliminary findings, required diagnostic workup, and initial management considerations to the oncology team.",
         "Dear Oncology Team,\n\nI am referring a 45-year-old male of Southeast Asian origin with clinical suspicion of nasopharyngeal carcinoma (NPC). Relevant risk factors include his geographic background, as NPC is more prevalent in individuals from Southeast Asia, and a history of tobacco and alcohol use, both of which are established risk factors for head and neck cancers. Epstein-Barr virus (EBV) infection is a major etiologic factor in NPC, and should be considered in this case.\n\nPreliminary findings include the presence of a neck mass, intermittent hearing loss, and an enlarged cervical lymph node on examination. These symptoms are consistent with NPC, which often presents with lymphadenopathy and may cause hearing loss due to Eustachian tube dysfunction. Early-stage NPC can be asymptomatic, so these findings warrant prompt investigation.\n\nThe recommended diagnostic workup includes:\n- Comprehensive medical history and physical examination, with attention to risk factors and family history.\n- Imaging studies: Contrast-enhanced CT or MRI of the head and neck to assess the primary tumor and nodal involvement, and PET/CT to evaluate for distant metastases.\n- Biopsy: Histopathological confirmation via biopsy of the nasopharyngeal lesion and/or fine-needle aspiration (FNA), fine-needle biopsy (FNB), or core needle biopsy (CNB) of the cervical lymph node.\n- Biomarker testing: Assessment for EBV DNA, PD-L1, and MSI-H/dMMR status, as these may inform prognosis and therapeutic options.\n\nInitial management considerations include evaluation of performance status to guide treatment planning, and discussion of fertility preservation options prior to initiation of therapy, as treatment may impact fertility. Dental and nutritional assessments are also advised due to the potential effects of head and neck cancer treatment on oral health and nutritional status. Please proceed with the recommended workup and multidisciplinary evaluation.",
         "Creative Generation",
         "The patient is a 45-year-old male of Southeast Asian origin.; The patient has a clinical suspicion of nasopharyngeal carcinoma (NPC).; The patient presents with a neck mass.; The patient experiences intermittent hearing loss.; The patient has a history of tobacco use.; The patient has a history of alcohol use.; NPC is more prevalent in individuals from Asia.; EBV infection is a major etiologic factor for NPC.; An examination reveals an enlarged cervical lymph node.; A thorough diagnostic workup is recommended.; Imaging studies including CT/MRI and PET/CT should be performed.; A biopsy of the nasopharyngeal lesion is necessary for histopathological confirmation.; Biomarker testing for EBV DNA, PD-L1, and MSI-H/dMMR should be conducted.; Performance status should be evaluated.; Fertility preservation options should be discussed prior to therapy.; Dental and nutritional assessments are advised due to potential treatment impacts.",
         "NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Most NPCs are related to Epstein-Barr virus (EBV) infection.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions; common symptoms include enlarged lymph nodes and hearing loss.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; Performance status is considered in NPC treatment planning.; Fertility may be affected by NPC treatment and should be discussed before therapy.; Dental health can be affected by head and neck cancer and its treatment."
        ],
        [
         "1921",
         "Medical-700264e4",
         "Medical",
         "Rewrite the key recommendations for NPC diagnosis and surveillance as a structured clinical protocol for a multidisciplinary tumor board. Include essential steps for staging, biomarker evaluation, and follow-up planning.",
         "**Nasopharyngeal Carcinoma (NPC): Multidisciplinary Clinical Protocol**\n\n1. Initial Assessment:\n   - Obtain a comprehensive medical history, including geographic origin (notably Asia, Native America, North Africa), family history, and risk factors such as tobacco and alcohol use, and potential EBV exposure.\n   - Document all current symptoms, including neck mass, hearing loss, nasal obstruction, or other head and neck complaints, recognizing that early NPC may be asymptomatic.\n\n2. Physical Examination:\n   - Perform a thorough head and neck examination, including nasopharyngeal fiberoptic endoscopy and assessment for cervical lymphadenopathy.\n\n3. Diagnostic Workup:\n   - Imaging: Order contrast-enhanced CT and/or MRI of the head and neck to assess the primary tumor and regional lymph nodes. PET/CT should be considered to evaluate for distant metastases. Ultrasound may be used to guide lymph node biopsy.\n   - Biopsy: Obtain tissue diagnosis via biopsy of the nasopharyngeal lesion and/or fine-needle aspiration (FNA), fine-needle biopsy (FNB), or core needle biopsy (CNB) of suspicious lymph nodes. If metastases are suspected, biopsy of metastatic sites should be performed as appropriate.\n\n4. Biomarker Evaluation:\n   - At diagnosis, perform biomarker testing for EBV DNA (plasma or tumor), MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden, as these may inform prognosis and therapeutic decision-making.\n\n5. Staging:\n   - Utilize the AJCC TNM system to classify tumor size (T), nodal involvement (N), and distant metastasis (M).\n   - Categorize disease as resectable, unresectable, locoregional, locally advanced, or metastatic based on imaging and clinical findings.\n\n6. Multidisciplinary Review and Initial Management Planning:\n   - Present the case at a multidisciplinary tumor board to review diagnostic findings and determine optimal management.\n   - Assess performance status to guide treatment selection.\n   - Conduct dental and nutritional evaluations prior to therapy due to the potential impact of treatment on oral health and nutrition.\n   - Discuss fertility preservation options with the patient before initiating therapy, as treatment may affect fertility.\n\n7. Surveillance and Follow-up Planning:\n   - Develop a surveillance plan including periodic physical examinations and imaging (CT, MRI, or PET/CT) as clinically indicated, particularly in the first 5 years post-treatment.\n   - Schedule serial EBV DNA testing for early detection of recurrence.\n   - Adjust follow-up intervals based on individual risk of recurrence and patient-specific factors.\n\nThis protocol ensures a comprehensive, evidence-based approach to the diagnosis, staging, biomarker evaluation, and surveillance of NPC, facilitating coordinated multidisciplinary care.",
         "Creative Generation",
         "The protocol is for nasopharyngeal carcinoma (NPC).; Initial assessment should include a comprehensive medical history.; Attention should be given to geographic origin, notably Asia, Native America, and North Africa.; Risk factors for NPC include tobacco use, alcohol use, and EBV exposure.; Symptom evaluation should assess for enlarged lymph nodes and hearing loss.; Early NPC may be asymptomatic.; A physical examination and imaging studies should be performed for diagnostic workup.; Imaging studies include CT, MRI, PET/CT, and ultrasound.; Histopathologic confirmation requires a biopsy of the nasopharyngeal lesion or lymph node.; Biomarker testing should include EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; Staging should utilize the AJCC TNM system.; The tumor should be classified based on size, nodal involvement, and distant metastasis.; A multidisciplinary review should assess performance status and dental and nutritional health.; Fertility preservation should be discussed when appropriate.; Surveillance should include periodic imaging and serial EBV DNA testing post-treatment.",
         "NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M).; NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic based on extent of disease.; Performance status is considered in NPC treatment planning.; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for staging and surveillance.; EBV DNA testing is performed before and after treatment for NPC."
        ],
        [
         "1922",
         "Medical-cc919ee4",
         "Medical",
         "As a patient education nurse, draft a public health announcement informing high-risk communities about nasopharyngeal carcinoma (NPC). Emphasize risk factors, warning signs, and the importance of early medical evaluation.",
         "**Public Health Announcement: Protect Yourself Against Nasopharyngeal Carcinoma (NPC)**\n\nNasopharyngeal carcinoma (NPC) is a type of cancer that develops in the nasopharynx, the area behind the nose and above the back of the throat. Certain communities—including people of Asian, Native American, and North African descent—are at higher risk, especially if they have been exposed to the Epstein-Barr virus (EBV). Additional risk factors include the use of tobacco and alcohol, which can further increase the likelihood of developing NPC.\n\nNPC often does not cause symptoms until it has reached an advanced stage. However, early warning signs may include a painless lump in the neck (enlarged lymph node), hearing loss, or a feeling of fullness in the ear. Other possible symptoms can be nasal congestion, nosebleeds, or persistent sore throat. Because these symptoms can be mistaken for other common conditions, it is important for individuals with risk factors to be vigilant.\n\nEarly detection greatly improves treatment outcomes. If you notice any of these warning signs or have risk factors for NPC, seek prompt medical evaluation. Diagnosis typically involves a thorough medical history, physical examination, imaging tests (such as CT or MRI scans), and a biopsy of any suspicious tissue. Your healthcare provider may also recommend EBV DNA testing and other assessments as part of the diagnostic process.\n\nTalk to your healthcare provider about your risk factors, the importance of regular checkups, and ways to reduce your risk. Early medical evaluation can make a significant difference in outcomes for nasopharyngeal carcinoma.",
         "Creative Generation",
         "Nasopharyngeal carcinoma (NPC) affects the area behind the nose and above the back of the throat.; People from Asia, Native America, and North Africa are at higher risk for NPC.; Exposure to the Epstein-Barr virus (EBV) increases the risk of NPC.; Use of tobacco and alcohol can also increase the risk of NPC.; NPC may not cause symptoms until it is advanced.; Warning signs of NPC include lumps in the neck and hearing loss.; Early detection of NPC is important.; Individuals with symptoms or risk factors should seek medical evaluation promptly.; Diagnosis of NPC involves a physical exam, imaging tests, and a biopsy.; Patients should talk to their healthcare provider about reducing risk and the importance of regular checkups.",
         "Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx.; NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Most NPCs are related to Epstein-Barr virus (EBV) infection.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions.; Symptom: Enlarged lymph nodes, hearing loss.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy."
        ],
        [
         "1923",
         "Medical-d96c57fa",
         "Medical",
         "You are a medical intern tasked with writing a SOAP (Subjective, Objective, Assessment, Plan) note for a patient newly diagnosed with Stage II nasopharyngeal carcinoma. Incorporate relevant history, exam findings, diagnostic results, and initial management steps.",
         "**S:** 38-year-old male of North African descent presents with a painless neck mass and occasional hearing loss. Reports no other significant symptoms. Past history notable for moderate tobacco and alcohol use.\n\n**O:** Physical exam reveals a 2-cm firm, non-tender lymph node in the left cervical chain. No oral or pharyngeal lesions visible. Imaging with CT and MRI shows a nasopharyngeal mass with ipsilateral lymphadenopathy. Biopsy confirms squamous cell carcinoma. EBV DNA detected in plasma. Performance status is ECOG 1. Dental and nutritional evaluations completed.\n\n**A:** Stage II nasopharyngeal carcinoma (NPC), squamous cell carcinoma subtype, EBV-associated, with cervical lymph node involvement. Risk factors include geographic origin and substance use. Good performance status.\n\n**P:** Multidisciplinary tumor board discussion. Begin definitive therapy per guidelines. Counsel patient regarding potential effects on fertility and oral health. Schedule baseline and surveillance EBV DNA testing. Continue nutritional and speech/swallowing support as indicated.",
         "Creative Generation",
         "The patient is a 38-year-old male of North African descent.; The patient presents with a painless neck mass.; The patient reports occasional hearing loss.; The patient has no other significant symptoms.; The patient's past history includes moderate tobacco use.; The patient's past history includes alcohol use.; Physical examination reveals a 2-cm firm, non-tender lymph node in the left cervical chain.; No oral or pharyngeal lesions are visible on examination.; Imaging with CT and MRI shows a nasopharyngeal mass with ipsilateral lymphadenopathy.; A biopsy confirms squamous cell carcinoma.; EBV DNA is detected in the patient's plasma.; The patient's performance status is ECOG 1.; Dental and nutritional evaluations have been completed.; The diagnosis is Stage II nasopharyngeal carcinoma (NPC).; The subtype of NPC is squamous cell carcinoma.; The NPC is EBV-associated with cervical lymph node involvement.; The patient has a good performance status.; A multidisciplinary tumor board discussion is planned.; Definitive therapy will begin per guidelines.; The patient will be counseled regarding potential effects on fertility and oral health.; Baseline and surveillance EBV DNA testing will be scheduled.; Nutritional and speech/swallowing support will continue as indicated.",
         "NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions; common symptoms include enlarged lymph nodes and hearing loss.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA.; NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M).; Performance status is considered in NPC treatment planning.; Dental health can be affected by head and neck cancer and its treatment.; Fertility may be affected by NPC treatment and should be discussed before therapy.; Nutrition assessment and speech and swallowing assessment are recommended in diagnostic method."
        ],
        [
         "1924",
         "Medical-caab7a58",
         "Medical",
         "You are a radiation oncologist preparing an initial case summary for a patient with locally advanced, unresectable nasopharyngeal carcinoma (NPC). Summarize the diagnostic findings, relevant biomarkers, staging, and multidisciplinary considerations for the tumor board.",
         "The patient is a 52-year-old male who presents with a large nasopharyngeal mass and multiple enlarged cervical lymph nodes. Diagnostic imaging with MRI and PET/CT reveals extensive locoregional disease involving the nasopharynx and regional lymph nodes, but no evidence of distant metastasis. Histopathological examination of the biopsy confirms squamous cell carcinoma, the most common subtype of nasopharyngeal carcinoma (NPC). Biomarker analysis demonstrates elevated Epstein-Barr virus (EBV) DNA levels and positive PD-L1 expression, both of which are relevant for prognosis and potential therapeutic options. According to the American Joint Committee on Cancer (AJCC) TNM staging system, the tumor is classified as locally advanced and unresectable. The patient's performance status is ECOG 2, which is an important consideration for treatment planning. Pre-treatment assessments, including dental and nutritional evaluations, have been completed to address potential complications from therapy. The patient has also received counseling regarding the possible impact of treatment on fertility. For optimal management, multidisciplinary input is recommended, including medical oncology for systemic therapy, speech and swallowing therapy for functional support, and comprehensive supportive care.",
         "Creative Generation",
         "The patient is a 52-year-old male.; The patient presents with a large nasopharyngeal mass.; The patient has multiple enlarged cervical lymph nodes.; Imaging with MRI and PET/CT demonstrates extensive locoregional disease.; There is no distant metastasis observed.; A biopsy confirms the squamous cell carcinoma subtype of NPC.; Biomarker analysis reveals elevated EBV DNA levels.; Biomarker analysis shows positive PD-L1 expression.; Staging per AJCC TNM system classifies the tumor as locally advanced and unresectable.; The patient's performance status is ECOG 2.; Pre-treatment dental and nutritional assessments have been completed.; The patient has been counseled about potential fertility impacts of therapy.; Multidisciplinary input from medical oncology, speech/swallowing therapy, and supportive care is recommended.",
         "Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M).; NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic based on extent of disease.; Performance status is considered in NPC treatment planning.; Dental health can be affected by head and neck cancer and its treatment.; Fertility may be affected by NPC treatment and should be discussed before therapy.; Nutrition assessment and speech and swallowing assessment are recommended in diagnostic method."
        ],
        [
         "1925",
         "Medical-048eef0e",
         "Medical",
         "You are a colorectal surgeon receiving a referral for a 45-year-old patient newly diagnosed with Stage 3 colon adenocarcinoma. Based on the clinical practice guideline, draft a surgical and perioperative management plan, including diagnostic confirmation, surgical intervention, adjuvant therapy, biomarker testing, and postoperative surveillance.",
         "Upon referral of the patient with Stage 3 colon adenocarcinoma, I would first confirm the diagnosis and staging with a colonoscopy and biopsy, supplemented by CT scan with contrast to assess for nodal involvement and distant metastases. Preoperative blood tests, including CBC, chemistry profile, and CEA, would be obtained for baseline assessment. All colon cancers should undergo testing for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) to guide postoperative therapy. The primary surgical approach would be a colectomy to remove the cancerous segment of the colon, with en bloc resection of adjacent lymph nodes. Intraoperatively, if primary anastomosis is not possible, a colostomy may be required. After recovery, adjuvant chemotherapy—typically FOLFOX or CAPEOX—should be initiated. Postoperative surveillance will include regular colonoscopy, CEA testing, and CT scans. The patient should also be counseled on genetic risk factors and offered referral to genetic counseling if appropriate.",
         "Creative Generation",
         "The patient is 45 years old.; The patient has been newly diagnosed with Stage 3 colon adenocarcinoma.; The diagnosis and staging will be confirmed with a colonoscopy and biopsy.; A CT scan with contrast will be used to assess for nodal involvement and distant metastases.; Preoperative blood tests will include CBC, chemistry profile, and CEA.; All colon cancers should undergo testing for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Testing for dMMR or MSI-H will guide postoperative therapy.; The primary surgical approach will be a colectomy to remove the cancerous segment of the colon.; En bloc resection of adjacent lymph nodes will be performed.; If primary anastomosis is not possible, a colostomy may be required.; Adjuvant chemotherapy, typically FOLFOX or CAPEOX, should be initiated after recovery.; Postoperative surveillance will include regular colonoscopy, CEA testing, and CT scans.; The patient should be counseled on genetic risk factors.; Referral to genetic counseling should be offered if appropriate.",
         "Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits.; Colonoscopy is the recommended diagnostic method for colon cancer, with polypectomy performed for removal of polyps.; CT with contrast is the main imaging test for staging and surveillance.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Colectomy is surgery to remove the cancerous part of the colon.; Colostomy diverts stool through an abdominal stoma if reconnection is not possible.; Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers.; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans.; Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing."
        ],
        [
         "1926",
         "Medical-80b6ffc1",
         "Medical",
         "Rewrite the clinical management of a young adult with newly diagnosed colon cancer into a formal discharge summary, ensuring inclusion of diagnostic workup, staging, biomarker assessment, surgical and adjuvant treatment, and fertility preservation counseling as per guidelines.",
         "Discharge Summary:\n\nPatient: [Name Redacted]\nAge: 32\nDiagnosis: Stage 2 colon adenocarcinoma\n\nHospital Course:\nThe patient presented with rectal bleeding and was diagnosed with colon adenocarcinoma following colonoscopy and biopsy. CT scan with contrast confirmed stage 2 disease with no lymph node or distant organ involvement. Baseline laboratory evaluation included CBC, chemistry profile, and CEA. Tumor tissue was tested for mismatch repair deficiency (dMMR) and found to be dMMR/MSI-H. The patient underwent segmental colectomy with primary anastomosis. Given dMMR/MSI-H status, adjuvant immunotherapy with a checkpoint inhibitor was recommended over standard chemotherapy. The patient received counseling regarding the risk of infertility associated with treatment and was offered sperm banking prior to therapy. Discharge instructions included scheduling for follow-up colonoscopy, CEA testing, and CT imaging as part of surveillance.",
         "Creative Generation",
         "The patient is 32 years old.; The patient has been diagnosed with Stage 2 colon adenocarcinoma.; The patient presented with rectal bleeding.; The diagnosis of colon adenocarcinoma was made following colonoscopy and biopsy.; A CT scan with contrast confirmed stage 2 disease.; There is no lymph node or distant organ involvement.; Baseline laboratory evaluation included CBC, chemistry profile, and CEA.; Tumor tissue was tested for mismatch repair deficiency (dMMR).; The tumor was found to be dMMR/MSI-H.; The patient underwent segmental colectomy with primary anastomosis.; Adjuvant immunotherapy with a checkpoint inhibitor was recommended due to dMMR/MSI-H status.; The patient received counseling regarding the risk of infertility associated with treatment.; The patient was offered sperm banking prior to therapy.; Discharge instructions included scheduling for follow-up colonoscopy, CEA testing, and CT imaging as part of surveillance.",
         "Colonoscopy is the recommended diagnostic method for colon cancer.; Stage 2 colon cancer invades or passes fourth layer, no lymph node involvement.; CT with contrast is the main imaging test for staging and surveillance.; Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.; Colectomy is surgery to remove the cancerous part of the colon.; Young adults should be counseled about fertility risks and preservation options before treatment.; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans."
        ],
        [
         "1927",
         "Medical-cf4e8f59",
         "Medical",
         "Imagine you are a genetic counselor receiving a patient with a new diagnosis of colon adenocarcinoma and a family history of colorectal cancer. Draft a counseling summary addressing inherited syndromes, genetic testing recommendations, implications for at-risk relatives, and surveillance strategies.",
         "As a genetic counselor, I would inform the patient that a family history of colorectal cancer increases the likelihood of inherited cancer syndromes, most commonly Lynch syndrome and familial adenomatous polyposis (FAP). I would recommend genetic testing for germline mutations in mismatch repair (MMR) genes associated with Lynch syndrome, as well as APC gene testing if FAP is suspected, in accordance with current guidelines. Identifying an inherited syndrome is important not only for the patient's management but also for at-risk relatives, who should be offered predictive genetic testing and, if positive, appropriate surveillance. For individuals with Lynch syndrome, earlier and more frequent colonoscopic surveillance is recommended to detect new or recurrent cancers at an early stage. I would discuss the implications of a positive genetic test, including the risk of other associated cancers, and provide information on the clinical features, risks, and recommended management strategies for both Lynch syndrome and FAP. Additionally, I would coordinate referrals for genetic testing, facilitate communication with family members regarding their potential risk, and outline surveillance strategies tailored to the specific syndrome identified.",
         "Creative Generation",
         "A family history of colorectal cancer increases the risk of inherited cancer syndromes.; Inherited cancer syndromes include Lynch syndrome and familial adenomatous polyposis (FAP).; Genetic testing for mismatch repair gene mutations associated with Lynch syndrome is recommended.; Genetic testing for APC gene mutations is recommended if FAP is suspected.; Identification of an inherited syndrome has implications for the patient and at-risk relatives.; At-risk relatives should be offered predictive testing.; At-risk relatives should be offered appropriate surveillance.; Regular colonoscopy at earlier and more frequent intervals is advised for patients with Lynch syndrome.; Information on the signs, risks, and management of Lynch syndrome and FAP will be provided.; Referrals for genetic testing and surveillance will be coordinated as per guidelines.",
         "Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk.; Family history of colorectal cancer is a risk factor.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; MMR gene mutations are genetic alterations associated with inherited syndromes.; First-degree relative with colorectal cancer is a recognized risk factor.; Surveillance after treatment includes colonoscopy.; Inherited syndromes include Lynch syndrome and FAP."
        ],
        [
         "1928",
         "Medical-ec48f89d",
         "Medical",
         "Transform the following clinical recommendations into a public health advisory for primary care providers: Highlight the importance of early detection, risk stratification, and guideline-based management of colon cancer.",
         "Public Health Advisory for Primary Care Providers: Early Detection and Management of Colon Cancer\n\nColon cancer is a leading cause of cancer-related morbidity and mortality. Early detection through colonoscopy and removal of precancerous polyps (adenomas) significantly reduces cancer risk. Providers should identify individuals with risk factors, such as a family history of colorectal cancer or inherited syndromes (Lynch syndrome, FAP), and refer them for genetic counseling and earlier surveillance. All patients diagnosed with colon cancer should have their tumors tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), as these biomarkers guide therapy. Post-treatment, ongoing surveillance with colonoscopy, CEA testing, and CT scans is essential to detect recurrence. Discuss fertility preservation options with young adults prior to initiating therapy.",
         "Creative Generation",
         "Colon cancer is a leading cause of cancer-related morbidity and mortality.; Early detection through colonoscopy significantly reduces cancer risk.; Removal of precancerous polyps (adenomas) is important for cancer prevention.; Providers should identify individuals with risk factors for colon cancer.; Risk factors include a family history of colorectal cancer and inherited syndromes.; Individuals with risk factors should be referred for genetic counseling.; Individuals with risk factors should be referred for earlier surveillance.; All patients diagnosed with colon cancer should have their tumors tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Testing for dMMR or MSI-H guides therapy.; Ongoing surveillance with colonoscopy, CEA testing, and CT scans is essential post-treatment.; Fertility preservation options should be discussed with young adults prior to initiating therapy.",
         "Most colon cancers start in polyps, especially adenomas.; Polypectomy removes polyps during colonoscopy.; Family history of colorectal cancer is a risk factor.; Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans.; Young adults should be counseled about fertility risks and preservation options before treatment."
        ],
        [
         "1929",
         "Medical-5b2ade97",
         "Medical",
         "You are a medical oncologist asked to summarize the evidence-based first-line treatment options for metastatic (Stage 4) colon cancer, including biomarker-driven therapy, surgical considerations, and palliative care integration.",
         "The first-line treatment of metastatic (Stage 4) colon cancer begins with confirmation of distant metastases using contrast-enhanced CT imaging. All patients should have their tumors tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), as these biomarkers guide therapy selection. For patients with dMMR/MSI-H tumors, immunotherapy with checkpoint inhibitors such as pembrolizumab or nivolumab (with or without ipilimumab) is preferred due to superior efficacy. For patients with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors, standard first-line systemic chemotherapy regimens include FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or CAPEOX (capecitabine and oxaliplatin). Surgical resection of the primary tumor or metastatic lesions may be considered in select patients with limited, resectable disease, particularly if it may improve survival or alleviate symptoms. Early integration of palliative care is recommended to manage symptoms, support quality of life, and address psychosocial needs. Ongoing surveillance with imaging and carcinoembryonic antigen (CEA) testing is essential to monitor treatment response and detect disease progression.",
         "Creative Generation",
         "For Stage 4 (metastatic) colon cancer, distant metastases must be confirmed with contrast-enhanced CT imaging.; All tumors must be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.; Examples of checkpoint inhibitors include pembrolizumab and nivolumab.; Systemic chemotherapy regimens such as FOLFOX or CAPEOX are recommended for pMMR/MSS tumors.; Surgical resection of the primary tumor or metastases may be considered for select patients.; Palliative care should be integrated early to address symptoms.; Palliative care aims to improve quality of life.; Surveillance with imaging and CEA testing is essential for monitoring treatment response.",
         "Stage 4 colon cancer has spread to distant organs (commonly liver or lungs).; CT with contrast is the main imaging test for staging and surveillance.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.; pMMR/MSS cancers are treated with chemotherapy.; FOLFOX and CAPEOX are recommended chemotherapy regimens.; Colectomy is surgery to remove the cancerous part of the colon.; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans."
        ],
        [
         "1930",
         "Medical-9d9b1ed1",
         "Medical",
         "Imagine you are a gastroenterologist evaluating a patient newly diagnosed with esophageal cancer. Write a comprehensive case summary that includes cancer subtype differentiation, staging considerations, diagnostic workup, and initial factors for treatment planning, referencing the relevant clinical practice guidelines.",
         "The patient presents with a new diagnosis of esophageal cancer. A comprehensive case summary begins with differentiation of the histological subtype: esophageal squamous cell carcinoma, which arises from the squamous cells lining the upper and middle esophagus, and esophageal adenocarcinoma, which originates from mucus-secreting cells typically in the lower esophagus and is often associated with Barrett esophagus. Accurate subtype identification is essential for guiding management. Staging is a critical next step and is based on the extent of tumor invasion (T), involvement of regional lymph nodes (N), and presence of distant metastases (M), following established staging systems such as the AJCC. Early-stage disease is confined to the esophagus without lymph node involvement; locoregional disease involves invasion into the esophageal wall and/or spread to regional lymph nodes or adjacent organs; metastatic disease is defined by distant spread, commonly to the liver, lungs, bone, or brain. The diagnostic workup should include a thorough medical history, blood tests, imaging studies (CT, PET scans), and endoscopic evaluation with biopsy for histopathological confirmation. Biomarker and genetic risk testing are recommended to identify potential therapeutic targets. For tumors at the esophagogastric junction, the Siewert classification is used to further refine staging and inform treatment strategy. Initial treatment planning should consider cancer subtype, anatomical location, and stage, as well as the patient's nutritional status and performance status, in accordance with current clinical practice guidelines. Multidisciplinary input is essential to optimize outcomes and tailor therapy to individual patient needs.",
         "Creative Generation",
         "The patient has a new diagnosis of esophageal cancer.; The first step is to determine the histological subtype of the cancer.; Esophageal squamous cell carcinoma originates from the squamous cells of the upper and middle esophagus.; Esophageal adenocarcinoma arises from the mucus-secreting cells in the lower esophagus.; Barrett esophagus is often associated with esophageal adenocarcinoma.; Staging is crucial for esophageal cancer.; Early-stage disease is confined to the esophagus without lymph node involvement.; Locoregional disease involves invasion of the esophageal wall and/or spread to regional lymph nodes or adjacent organs.; Metastatic disease is defined by distant spread to organs such as the liver, lung, bone, or brain.; The diagnostic workup includes blood tests.; Imaging studies such as CT or PET scans are part of the diagnostic workup.; Endoscopic evaluation with biopsy is necessary for histopathological confirmation.; Biomarker testing is included in the diagnostic workup.; Assessment of genetic risk factors is part of the diagnostic workup.; Siewert classification assists in staging tumors at the esophagogastric junction.; Treatment planning is based on cancer type, anatomical location, and stage.; The patient's nutritional status and performance are considered in treatment planning.",
         "Esophageal squamous cell carcinoma starts in squamous cells of the esophagus.; Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus.; Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma.; Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Siewert types are used to stage tumors at the esophagogastric junction.; Treatment planning is based on cancer type, location, and stage."
        ],
        [
         "1931",
         "Medical-09c35fc8",
         "Medical",
         "You are a medical oncologist preparing a multidisciplinary treatment plan for a patient diagnosed with locoregional esophageal adenocarcinoma at the esophagogastric junction. Detail your diagnostic confirmation steps, staging process, and key considerations for therapy selection, using the guideline.",
         "For this case of locoregional esophageal adenocarcinoma at the esophagogastric junction, I would initiate comprehensive diagnostic confirmation with endoscopic biopsy to determine histology, supported by blood tests and imaging studies to assess extent of disease. The Siewert classification will be applied for precise staging at the esophagogastric junction. The staging process distinguishes locoregional disease, where the tumor has invaded the esophageal wall and/or spread to regional lymph nodes or nearby organs, from early-stage or metastatic disease. Biomarker and genetic risk testing will be included to identify potential therapeutic targets. Nutritional assessment and evaluation of performance status are essential components of the pre-treatment workup. The treatment plan will be tailored based on cancer type (adenocarcinoma), anatomical location (esophagogastric junction), and locoregional stage, in accordance with current multidisciplinary guidelines.",
         "Creative Generation",
         "The patient has locoregional esophageal adenocarcinoma at the esophagogastric junction.; Comprehensive diagnostic confirmation begins with an endoscopic biopsy to determine histology.; Blood tests and imaging studies are used to assess the extent of the disease.; Siewert classification is applied for precise staging at the esophagogastric junction.; The staging process distinguishes locoregional disease from early-stage or metastatic disease.; Locoregional disease involves tumor invasion of the esophageal wall and/or spread to regional lymph nodes or nearby organs.; Biomarker and genetic risk testing are included to identify potential therapeutic targets.; Nutritional assessment is essential in the pre-treatment workup.; Evaluation of performance status is an important component of the pre-treatment workup.; The treatment plan is tailored based on cancer type, anatomical location, and locoregional stage.",
         "Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus.; Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs.; Siewert types are used to stage tumors at the esophagogastric junction.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Treatment planning is based on cancer type, location, and stage.; Nutritional assessment and performance status are part of the diagnostic method."
        ],
        [
         "1932",
         "Medical-bc7d17ab",
         "Medical",
         "Transform the clinical facts into a formal discharge summary for a patient with metastatic esophageal squamous cell carcinoma, referencing relevant staging, diagnostic, and treatment planning considerations from the guideline.",
         "**Discharge Summary**\n\nDiagnosis: Metastatic esophageal squamous cell carcinoma\n\nHospital Course: The patient was admitted for evaluation and management of esophageal cancer. The diagnostic workup included comprehensive blood tests, cross-sectional imaging with CT and PET scans, endoscopic examination, and tissue biopsy. Pathology confirmed squamous cell carcinoma originating in the middle esophagus, which is a typical anatomical site for this histologic subtype. Staging investigations demonstrated metastatic disease with involvement of the liver and lung, consistent with advanced (stage IV) esophageal cancer. Biomarker and genetic risk testing were performed to guide potential targeted therapies and further inform prognosis. Multidisciplinary tumor board review was conducted, and treatment planning considered the cancer type, anatomical location, extent of metastatic spread, and the patient's performance status. Given the metastatic stage, palliative systemic therapy was recommended as per current guidelines. Nutritional assessment was performed due to the patient's risk of dysphagia and weight loss, and supportive care measures were initiated. The patient was discharged in stable condition with a coordinated follow-up plan for oncology evaluation, ongoing supportive care, and symptom management.",
         "Creative Generation",
         "The patient has metastatic esophageal squamous cell carcinoma.; The patient was admitted for evaluation and management of esophageal cancer.; The diagnostic workup included blood tests.; Imaging studies such as CT and PET scans were part of the diagnostic workup.; Endoscopic examination and biopsy confirmed squamous cell carcinoma of the esophagus.; Staging revealed metastatic disease with involvement of the liver and lung.; Biomarker and genetic risk testing were performed.; The tumor originated in the middle esophagus.; Multidisciplinary discussions recommended palliative systemic therapy.; Palliative therapy is based on the metastatic stage, primary tumor type, and patient performance status.; A nutritional assessment was conducted due to the risk of dysphagia and weight loss.; The patient was discharged with a follow-up plan for oncology and supportive care.",
         "Esophageal squamous cell carcinoma starts in squamous cells of the esophagus.; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Treatment planning is based on cancer type, location, and stage.; Nutritional assessment and performance status are part of the diagnostic method.; Anatomical location for squamous cell carcinoma includes the middle esophagus."
        ],
        [
         "1933",
         "Medical-9b2a1d38",
         "Medical",
         "As a primary care physician, draft a referral note to an oncology center for a patient with Barrett esophagus and new-onset dysphagia, incorporating risk stratification and diagnostic recommendations from the guidelines.",
         "**Referral Note**\n\nPatient: [Name Redacted]\nDOB: [Redacted]\n\nReason for Referral: Barrett esophagus with new-onset dysphagia\n\nSummary: The patient has a history of Barrett esophagus, a recognized precancerous condition for esophageal adenocarcinoma. He now presents with progressive dysphagia. Given the increased risk of malignant transformation, prompt evaluation for possible esophageal cancer is warranted. I recommend a comprehensive diagnostic workup including endoscopy with biopsy, imaging studies, blood tests, biomarker testing, and genetic risk assessment. Please consider staging and Siewert classification if a lesion is identified at the esophagogastric junction. Nutritional assessment should be performed due to risk of malnutrition. Thank you for your evaluation and management.",
         "Creative Generation",
         "The patient has Barrett esophagus and new-onset dysphagia.; Barrett esophagus is a recognized precancerous condition for esophageal adenocarcinoma.; The patient presents with progressive dysphagia.; Prompt evaluation for possible esophageal cancer is warranted due to increased risk of malignant transformation.; A comprehensive diagnostic workup is recommended.; The diagnostic workup should include endoscopy with biopsy.; Imaging studies and blood tests are part of the diagnostic recommendations.; Biomarker testing and genetic risk assessment should be included.; Staging and Siewert classification should be considered if a lesion is identified at the esophagogastric junction.; Nutritional assessment should be performed due to the risk of malnutrition.",
         "Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Siewert types are used to stage tumors at the esophagogastric junction.; Treatment planning is based on cancer type, location, and stage.; Nutritional assessment is part of the diagnostic method."
        ],
        [
         "1934",
         "Medical-45390bd2",
         "Medical",
         "Rewrite the core clinical recommendations into a public health advisory aimed at increasing awareness of esophageal cancer risk factors, early detection, and diagnostic pathways.",
         "**Public Health Advisory: Esophageal Cancer Awareness and Early Detection**\n\nEsophageal cancer arises from the inner lining of the esophagus and may develop as either squamous cell carcinoma or adenocarcinoma. Risk factors include the presence of Barrett esophagus, a precancerous condition that increases the likelihood of adenocarcinoma. Early-stage esophageal cancer is often asymptomatic and confined to the esophagus, while advanced stages may involve spread to lymph nodes or distant organs such as the liver, lungs, bones, and brain. Early detection is critical and involves blood tests, imaging, endoscopy, biopsy, and assessment of biomarkers and genetic risk. If symptoms such as persistent difficulty swallowing occur, prompt medical evaluation is advised. Comprehensive treatment planning requires accurate cancer type, location, and stage determination. Public awareness and timely screening can improve outcomes for those at risk.",
         "Creative Generation",
         "Esophageal cancer arises from the inner lining of the esophagus.; Esophageal cancer may develop as either squamous cell carcinoma or adenocarcinoma.; Risk factors for esophageal cancer include Barrett esophagus.; Barrett esophagus increases the likelihood of adenocarcinoma.; Early-stage esophageal cancer is often asymptomatic and confined to the esophagus.; Advanced stages of esophageal cancer may involve spread to lymph nodes or distant organs.; Distant organs affected may include the liver, lungs, bones, and brain.; Early detection of esophageal cancer is critical.; Early detection involves blood tests, imaging, endoscopy, biopsy, and assessment of biomarkers and genetic risk.; Symptoms such as persistent difficulty swallowing should prompt medical evaluation.; Comprehensive treatment planning requires accurate determination of cancer type, location, and stage.; Public awareness and timely screening can improve outcomes for those at risk.",
         "Esophageal cancer starts in the inner lining of the esophagus.; Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma.; Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes.; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Treatment planning is based on cancer type, location, and stage."
        ],
        [
         "1935",
         "Medical-dca8ac49",
         "Medical",
         "Imagine you are a hematopathologist receiving a referral for a 32-year-old male with a large mediastinal mass and supraclavicular lymphadenopathy. Based on the provided clinical practice guideline, write a diagnostic summary that outlines the differential diagnosis, key histopathological features, and the necessary steps to confirm mediastinal gray zone lymphoma (MGZL).",
         "Diagnostic Summary:\n\nThis 32-year-old male presents with a large mediastinal mass and supraclavicular lymphadenopathy. The differential diagnosis includes mediastinal gray zone lymphoma (MGZL), primary mediastinal B-cell lymphoma (PMBL), and classical Hodgkin lymphoma (CHL), as these entities share overlapping clinical and histopathological features. MGZL is characterized by large tumor cells that may vary in size and often resemble Reed-Sternberg cells—large, abnormal lymphocytes that may contain more than one nucleus. Key histopathological features to assess include the presence and morphology of Reed-Sternberg-like cells, the overall cellular architecture, and features intermediate between PMBL and CHL. To confirm MGZL, a thorough histological evaluation by an expert hematopathologist is essential, supported by immunophenotyping with a comprehensive panel of markers to identify characteristics of both PMBL and CHL. Accurate diagnosis is critical, as MGZL is distinct from other mediastinal lymphomas and requires tailored management. The diagnostic process should also exclude extra-mediastinal disease, which would favor a diagnosis of diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS). The final diagnosis will inform treatment planning, which typically involves chemotherapy, with the addition of rituximab if tumor cells express CD20, and consideration of involved-site radiation therapy (ISRT) for localized disease.",
         "Creative Generation",
         "The patient is a 32-year-old male with a large mediastinal mass and supraclavicular lymphadenopathy.; The differential diagnosis includes mediastinal gray zone lymphoma (MGZL).; Other differential diagnoses include primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (CHL).; The differential diagnoses are based on overlapping clinical and histopathological features.; Histological evaluation is essential for diagnosis.; Reed-Sternberg cells are important in the histological evaluation.; Diagnosis of MGZL requires an expert hematopathologist review.; Immunophenotyping and a comprehensive panel of markers should be employed.; The final diagnosis will guide appropriate therapy.; Therapy may include chemotherapy with or without rituximab.",
         "MGZL is characterized by a large mediastinal mass.; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth.; Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; Reed-Sternberg cells are characteristic histopathological features in MGZL.; Diagnosis of MGZL requires expert hematopathologist review."
        ],
        [
         "1936",
         "Medical-e89fa155",
         "Medical",
         "You are an oncology fellow tasked with constructing an initial treatment plan for a patient newly diagnosed with localized mediastinal gray zone lymphoma (MGZL). Integrate the guideline’s recommendations regarding therapeutic modalities and patient characteristics.",
         "Initial Treatment Plan:\n\nFor this patient with newly diagnosed, localized mediastinal gray zone lymphoma (MGZL), the recommended initial treatment is systemic chemotherapy, which serves as the cornerstone of therapy. If the tumor cells express CD20, rituximab may be added to the chemotherapy regimen to form chemoimmunotherapy, as this approach has been associated with improved outcomes in similar lymphomas. Given the localized presentation, involved-site radiation therapy (ISRT) should be considered following systemic therapy to enhance local disease control. This treatment strategy is supported by the patient's age (commonly 20–40 years) and the presence of a large mediastinal mass, which are characteristic features of MGZL. Management should involve a multidisciplinary team, including medical and radiation oncology, and regular assessment of treatment response. Referral to a cancer center with expertise in gray zone lymphomas and consideration of clinical trial enrollment may also be appropriate.",
         "Creative Generation",
         "The patient has newly diagnosed, localized mediastinal gray zone lymphoma (MGZL).; Chemotherapy is recommended as the foundation of treatment.; Rituximab may be added to create a chemoimmunotherapy regimen.; The addition of rituximab is based on current evidence for improved outcomes.; Involved-site radiation therapy (ISRT) should be considered as an adjunct to systemic therapy.; The patient's age is within the typical 20–40 year range.; Mediastinal involvement supports the treatment approach.; Multidisciplinary collaboration with radiation oncology is crucial.; Regular assessment of treatment response is important.",
         "MGZL is usually treated with chemotherapy.; Rituximab may be added to chemotherapy for chemoimmunotherapy.; Involved-site radiation therapy (ISRT) may be added in localized MGZL.; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth.; MGZL is characterized by a large mediastinal mass."
        ],
        [
         "1937",
         "Medical-de2ed9e3",
         "Medical",
         "Transform the core clinical and pathological features of mediastinal gray zone lymphoma (MGZL) into a formal referral letter from a primary care physician to a hematology specialist.",
         "Referral Letter:\n\nDear Hematology Specialist,\n\nI am referring a 28-year-old male who presents with a rapidly enlarging mediastinal mass and supraclavicular lymphadenopathy. Imaging studies confirm a bulky mediastinal tumor. Histopathological examination has revealed the presence of Reed-Sternberg cells. Given the overlap of features between primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), I am seeking your expert evaluation for possible mediastinal gray zone lymphoma (MGZL). I recommend expert hematopathologist review to establish a definitive diagnosis and guide management, including consideration of chemoimmunotherapy and potential involved-site radiation therapy.\n\nSincerely,\n[Referring Physician]",
         "Creative Generation",
         "The patient is a 28-year-old male with a rapidly enlarging mediastinal mass and supraclavicular lymphadenopathy.; Imaging studies confirm a bulky mediastinal tumor.; Histopathological examination revealed the presence of Reed-Sternberg cells.; There is an overlap of features between primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; An expert evaluation is sought for possible mediastinal gray zone lymphoma (MGZL).; Expert hematopathologist review is recommended to establish a definitive diagnosis.; Management may include consideration of chemoimmunotherapy.; Involved-site radiation therapy may also be considered.",
         "MGZL is characterized by a large mediastinal mass.; Lymph nodes above the collar bone (supraclavicular) may be involved.; Reed-Sternberg cells are characteristic histopathological features in MGZL.; Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; Diagnosis of MGZL requires expert hematopathologist review."
        ],
        [
         "1938",
         "Medical-6956692c",
         "Medical",
         "Rewrite the main findings and recommendations regarding non-mediastinal gray zone lymphoma into a discharge summary for a 68-year-old patient diagnosed with this entity, highlighting clinical presentation, diagnostic process, and treatment considerations.",
         "Discharge Summary:\n\nPatient: [Name], 68-year-old\nDiagnosis: Non-mediastinal gray zone lymphoma\n\nClinical Presentation:\nThe patient, a 68-year-old, presented with generalized lymphadenopathy and evidence of both bone marrow and extranodal involvement, consistent with advanced-stage disease. Notably, there was no mediastinal mass identified, which distinguishes this presentation from mediastinal gray zone lymphoma.\n\nDiagnostic Process:\nDiagnosis was established through histopathological and immunophenotypic evaluation, which revealed features characteristic of gray zone lymphoma. The absence of mediastinal involvement, combined with advanced-stage findings such as bone marrow and extranodal disease, supported the diagnosis of non-mediastinal gray zone lymphoma. According to current guidelines, cases with extra-mediastinal disease are classified and managed as diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS).\n\nTreatment Considerations:\nNon-mediastinal gray zone lymphomas predominantly affect older adults and are associated with a higher incidence of bone marrow and extranodal involvement compared to mediastinal cases. These lymphomas often present at an advanced stage. The recommended management aligns with treatment protocols for DLBCL-NOS, which typically involve systemic chemotherapy. The patient will be referred for systemic chemotherapy as per DLBCL-NOS protocols. Ongoing follow-up will focus on monitoring response in both marrow and extranodal sites. Consideration of supportive care and advance care planning is also recommended, given the advanced stage of disease.",
         "Creative Generation",
         "The patient is a 68-year-old diagnosed with non-mediastinal gray zone lymphoma.; The patient presented with generalized lymphadenopathy.; There is evidence of bone marrow and extranodal involvement.; No mediastinal mass was observed in the patient.; Histopathological and immunophenotypic studies demonstrated features consistent with gray zone lymphoma.; The absence of mediastinal disease led to the diagnosis of non-mediastinal gray zone lymphoma.; Non-mediastinal gray zone lymphomas are more common in older adults.; Non-mediastinal gray zone lymphomas tend to present at advanced stages.; Management typically follows protocols for diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS).; The patient will be referred for systemic chemotherapy as per DLBCL-NOS protocols.; Follow-up will include monitoring for marrow and extranodal disease response.",
         "Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement.; Sites of involvement include bone marrow involvement and extranodal disease.; Non-mediastinal gray zone lymphomas often present as advanced-stage disease.; If extra-mediastinal disease: Diagnose as DLBCL-NOS.; Treatment protocols for advanced-stage or extra-mediastinal disease align with those for DLBCL-NOS."
        ],
        [
         "1939",
         "Medical-27b6e451",
         "Medical",
         "You are drafting a public health information sheet for primary care providers on the recognition and referral of patients with suspected mediastinal gray zone lymphoma (MGZL). Summarize the key clinical features, diagnostic approach, and referral recommendations using evidence from the guideline.",
         "Information Sheet: Recognizing and Referring Mediastinal Gray Zone Lymphoma (MGZL)\n\nKey Clinical Features:\n- MGZL typically presents as a large mediastinal mass, often with supraclavicular lymph node involvement.\n- Most affected individuals are aged 20–40 years and assigned male at birth.\n\nDiagnostic Approach:\n- Histopathological assessment is critical, with Reed-Sternberg cells often observed.\n- MGZL shares overlapping features with both primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), making diagnosis challenging.\n- An expert hematopathologist review is required for accurate classification.\n\nReferral Recommendations:\n- Refer patients with unexplained mediastinal masses, especially in young males, for specialist hematology evaluation.\n- Ensure tissue samples are reviewed by a hematopathology expert to guide appropriate therapy, including consideration of chemoimmunotherapy and involved-site radiation therapy in localized cases.",
         "Creative Generation",
         "Mediastinal gray zone lymphoma (MGZL) typically presents as a large mediastinal mass.; MGZL often involves supraclavicular lymph node involvement.; Most affected individuals are aged 20–40 years.; Most affected individuals are assigned male at birth.; Histopathological assessment is critical for diagnosis.; Reed-Sternberg cells are often observed in MGZL.; MGZL shares overlapping features with primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; An expert hematopathologist review is required for accurate classification.; Patients with unexplained mediastinal masses should be referred for specialist hematology evaluation.; Tissue samples should be reviewed by a hematopathology expert to guide appropriate therapy.",
         "MGZL is characterized by a large mediastinal mass.; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth.; Lymph nodes above the collar bone (supraclavicular) may be involved.; Reed-Sternberg cells are characteristic histopathological features in MGZL.; Diagnosis of MGZL requires expert hematopathologist review."
        ],
        [
         "1940",
         "Medical-1bd20d18",
         "Medical",
         "Imagine you are a gynecologic oncologist receiving a referral for a 32-year-old woman with a recent diagnosis of stage IB1 squamous cell carcinoma of the cervix. The patient wishes to preserve fertility. Draft a detailed treatment plan, including diagnostic confirmation, staging, treatment options, and fertility preservation strategies, referencing the latest clinical practice guidelines.",
         "As a gynecologic oncologist, my initial approach would involve confirming the diagnosis of stage IB1 squamous cell carcinoma of the cervix through cervical biopsy and reviewing the pathology. Comprehensive staging should be performed using the FIGO system, with pelvic MRI and/or CT scan to evaluate the extent of local disease and assess for lymph node involvement. Baseline laboratory studies, including a complete blood count and assessment of organ function, should also be obtained. Given the patient's strong desire for fertility preservation and the early stage of her disease, I would discuss fertility-sparing surgical options in detail, specifically radical trachelectomy with pelvic lymph node dissection or sentinel lymph node biopsy, as recommended by current clinical guidelines. Referral to a fertility specialist prior to treatment initiation is advised to discuss fertility preservation strategies and reproductive planning. Ovarian transposition may be considered to preserve ovarian function if adjuvant pelvic radiation is anticipated. The treatment plan should be developed in a multidisciplinary setting, involving reproductive endocrinology as appropriate. Regular surveillance with physical examinations and imaging will be essential post-treatment. Supportive care, psychosocial support, and discussion of clinical trial opportunities should be integrated throughout the care process.",
         "Creative Generation",
         "The initial step is to confirm the diagnosis of stage IB1 squamous cell carcinoma with a cervical biopsy.; Complete staging is ensured using the FIGO system.; Pelvic MRI and/or CT scan are used to assess local and nodal involvement.; Fertility-sparing surgery is an option for the patient.; Radical trachelectomy with pelvic lymph node dissection or sentinel lymph node biopsy is discussed.; Ovarian transposition may be considered to preserve ovarian function if adjuvant therapy is needed.; Regular follow-up with physical exams and imaging is essential for surveillance.; Supportive care is provided throughout the process.; The option of clinical trial participation is discussed.",
         "Cervical biopsy is the primary diagnostic method for cervical cancer.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases.; Ovarian transposition is a fertility preservation strategy.; Surveillance after treatment includes regular physical exams and imaging as indicated.; Clinical trials are an option for all stages of cervical cancer."
        ],
        [
         "1941",
         "Medical-47ec9e64",
         "Medical",
         "As a medical intern in the oncology ward, write a referral letter to a radiation oncologist for a patient with newly diagnosed FIGO stage IIB cervical cancer. Your note should summarize the diagnostic findings, risk factors, and rationale for the recommended treatment approach.",
         "Dear Radiation Oncology Team,\n\nI am referring Ms. J, a 45-year-old woman recently diagnosed with FIGO stage IIB squamous cell carcinoma of the cervix. Her diagnosis was established via cervical biopsy following symptoms of abnormal vaginal bleeding and pelvic pain. Imaging with pelvic MRI and PET/CT confirmed parametrial invasion without distant metastasis. Notable risk factors include a history of smoking and chronic immunosuppression due to HIV infection. Given the locally advanced disease, concurrent chemoradiation with external beam radiation therapy (EBRT) and cisplatin-based chemotherapy is recommended as per current guidelines. Please assess for initiation of chemoradiation and consider brachytherapy for local control. Thank you for your expert evaluation.",
         "Creative Generation",
         "Ms. J is a 45-year-old woman diagnosed with FIGO stage IIB squamous cell carcinoma of the cervix.; Her diagnosis was established via cervical biopsy.; She presented with symptoms of abnormal vaginal bleeding and pelvic pain.; Imaging with pelvic MRI and PET/CT confirmed parametrial invasion without distant metastasis.; Notable risk factors include a history of smoking and chronic immunosuppression due to HIV infection.; Concurrent chemoradiation with external beam radiation therapy (EBRT) and cisplatin-based chemotherapy is recommended.",
         "Cervical biopsy is the primary diagnostic method for cervical cancer.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Smoking increases the risk of cervical cancer.; Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer.; Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer.; External beam radiation therapy (EBRT) and brachytherapy are used for local control."
        ],
        [
         "1942",
         "Medical-a4a83818",
         "Medical",
         "Transform the guideline information into a comprehensive discharge summary for a patient with stage IIIB adenocarcinoma of the cervix who has completed chemoradiation. Include the diagnosis, staging, treatments provided, biomarkers tested, and follow-up recommendations.",
         "Discharge Summary:\n\nDiagnosis: Stage IIIB adenocarcinoma of the cervix, confirmed by cervical biopsy.\n\nStaging: Pelvic MRI and PET/CT indicated parametrial extension and involvement of the pelvic sidewall, consistent with FIGO IIIB disease.\n\nTreatment: The patient completed concurrent chemoradiation, consisting of external beam radiation therapy (EBRT), brachytherapy, and weekly cisplatin. Biomarker testing for PD-L1, MSI, and TMB was performed to inform potential future systemic therapy options.\n\nFollow-up: The patient will undergo regular physical examinations and imaging as indicated for surveillance. Supportive care and palliative care resources have been discussed. Smoking cessation is strongly encouraged to improve long-term outcomes. Participation in clinical trials will be considered if recurrent or metastatic disease develops.",
         "Creative Generation",
         "The diagnosis is stage IIIB adenocarcinoma of the cervix, confirmed by cervical biopsy.; Staging indicated parametrial extension and involvement of the pelvic sidewall.; The staging is consistent with FIGO IIIB disease.; The patient completed concurrent chemoradiation.; The treatment consisted of external beam radiation therapy (EBRT), brachytherapy, and weekly cisplatin.; Biomarker testing for PD-L1, MSI, and TMB was performed.; Regular physical examinations and imaging are recommended for follow-up.; Supportive care and palliative care resources have been discussed.; Smoking cessation is strongly encouraged to improve long-term outcomes.; Participation in clinical trials will be considered if recurrent or metastatic disease develops.",
         "Adenocarcinoma and adenosquamous carcinoma are less common subtypes.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer.; External beam radiation therapy (EBRT) and brachytherapy are used for local control.; Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer.; Surveillance after treatment includes regular physical exams and imaging as indicated.; Supportive care and palliative care are integral for advanced or metastatic disease.; Smoking cessation improves treatment outcomes.; Clinical trials are an option for all stages of cervical cancer."
        ],
        [
         "1943",
         "Medical-e0a374bb",
         "Medical",
         "You are a public health officer tasked with creating an evidence-based public health advisory to reduce cervical cancer incidence in your community. Incorporate screening, prevention, risk factor modification, and follow-up recommendations from the clinical practice guideline.",
         "**Public Health Advisory: Preventing Cervical Cancer in Our Community**\n\nCervical cancer is a preventable disease that remains a significant threat to women's health. The majority of cases are caused by persistent infection with high-risk human papillomavirus (HPV) types, especially HPV16 and HPV18. To reduce the incidence of cervical cancer, we recommend the following evidence-based strategies:\n\n**Screening:**\n- Regular cervical cancer screening with Pap smears (cytology) is essential for early detection of precancerous changes (cervical dysplasia) and cancer. Early identification allows for timely treatment and can prevent progression to invasive cancer.\n- All eligible individuals should participate in recommended screening programs based on age and risk factors.\n\n**Prevention:**\n- HPV vaccination is highly effective in preventing infection with the most common high-risk HPV types and is recommended for eligible individuals.\n- Safe sexual practices can reduce the risk of HPV transmission.\n\n**Risk Factor Modification:**\n- Smoking significantly increases the risk of cervical cancer. We strongly encourage tobacco cessation and offer resources for quitting.\n- Immunosuppression, including HIV infection, also increases risk. Individuals with immunosuppression should adhere to recommended screening intervals and seek regular medical care.\n- Maintaining a healthy lifestyle, including a balanced diet and regular exercise, may contribute to overall cancer risk reduction.\n\n**Follow-up Recommendations:**\n- Individuals with abnormal screening results or a history of cervical dysplasia or cancer should receive appropriate follow-up, including physical examinations and imaging as indicated.\n- Ongoing surveillance is important for early detection of recurrence or new disease.\n\n**Additional Resources:**\n- Participation in clinical trials may provide access to new prevention and treatment options.\n- Community education and outreach are vital to increase awareness and participation in prevention and screening programs.\n\nBy following these guidelines, we can work together to reduce the burden of cervical cancer in our community.",
         "Creative Generation",
         "Cervical cancer is a significant threat to women's health.; Most cases are caused by persistent infection with high-risk human papillomavirus (HPV) types.; Regular screening with Pap smears is essential for early detection and prevention of cervical cancer.; Cervical dysplasia can be treated to prevent progression to cancer.; Risk factors for cervical cancer include smoking and immunosuppression, including HIV infection.; Eligible individuals are urged to participate in screening programs.; Tobacco use should be avoided.; Follow-up after abnormal screening or treatment should include physical exams and imaging as appropriate.; Clinical trials are available and may offer additional options for prevention and care.",
         "Most cervical cancers are caused by long-term infection with human papillomavirus (HPV).; HPV16 and HPV18 are high-risk HPV types associated with cervical cancer.; Pap smear is used for cervical cancer screening.; Cervical dysplasia (CIN) can progress to cervical cancer if untreated.; Smoking increases the risk of cervical cancer.; Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer.; Surveillance after treatment includes regular physical exams and imaging as indicated.; Clinical trials are an option for all stages of cervical cancer."
        ],
        [
         "1944",
         "Medical-11abd566",
         "Medical",
         "Reformat the following clinical scenario into a structured SOAP note: A 55-year-old woman presents with abnormal vaginal bleeding and fatigue. Imaging and biopsy confirm stage IVA neuroendocrine carcinoma of the cervix. She has a history of smoking and multiple sexual partners. Document the relevant findings, assessment, and plan based on guideline recommendations.",
         "SOAP Note:\n\nSubjective: 55-year-old female presents with abnormal vaginal bleeding and fatigue. Past medical history significant for chronic tobacco use and multiple sexual partners.\n\nObjective: On examination, watery vaginal discharge and pelvic pain noted. Imaging (CT and MRI) reveals local invasion into adjacent pelvic organs, consistent with FIGO stage IVA. Cervical biopsy confirms neuroendocrine carcinoma of the cervix.\n\nAssessment: Advanced (stage IVA) neuroendocrine carcinoma of the cervix with poor prognostic features (aggressive histology, high-risk behaviors).\n\nPlan:\n- Initiate systemic therapy, including platinum-based chemotherapy and consider targeted or immunotherapy based on biomarker testing (PD-L1, MSI, MMR, TMB, HER2, RET, NTRK).\n- Consider external beam radiation therapy (EBRT) and/or brachytherapy for local control as appropriate.\n- Engage palliative care for symptom management and supportive care.\n- Counsel on smoking cessation to improve treatment outcomes.\n- Offer clinical trial enrollment if eligible.",
         "Creative Generation",
         "The patient is a 55-year-old woman presenting with abnormal vaginal bleeding and fatigue.; Her past medical history includes chronic tobacco use and multiple sexual partners.; On examination, watery vaginal discharge and pelvic pain were noted.; Imaging (CT and MRI) reveals local invasion into adjacent pelvic organs.; The findings are consistent with FIGO stage IVA.; Cervical biopsy confirms neuroendocrine carcinoma of the cervix.; The assessment indicates advanced (stage IVA) neuroendocrine carcinoma of the cervix with poor prognostic features.; The plan includes initiating systemic therapy with platinum-based chemotherapy.; Targeted or immunotherapy may be considered based on biomarker testing.; External beam radiation therapy (EBRT) and/or brachytherapy may be considered for local control.; Palliative care will be engaged for symptom management and supportive care.; Counseling on smoking cessation is recommended to improve treatment outcomes.; Clinical trial enrollment will be offered if eligible.",
         "Abnormal vaginal bleeding and fatigue are symptoms associated with cervical cancer.; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Systemic therapy options include platinum-based chemotherapy, targeted therapy, and immunotherapy.; Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer.; Supportive care and palliative care are integral for advanced or metastatic disease.; Smoking increases the risk of cervical cancer.; Smoking cessation improves treatment outcomes.; Clinical trials are an option for all stages of cervical cancer."
        ],
        [
         "1945",
         "Medical-c8a65fec",
         "Medical",
         "You are a hematology fellow evaluating a 28-year-old patient who presents with painless cervical lymphadenopathy. Based on the clinical practice guideline for Hodgkin lymphoma, compose a detailed diagnostic summary outlining the steps and rationale for confirming the diagnosis and differentiating between classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).",
         "The diagnostic evaluation of a 28-year-old presenting with painless cervical lymphadenopathy should begin with a comprehensive health history and physical examination, with particular attention to the distribution and characteristics of lymphadenopathy and the presence of systemic 'B' symptoms (fever, night sweats, weight loss). Initial laboratory studies, including complete blood count and other relevant blood tests, help assess for cytopenias or organ involvement. Imaging studies, such as CT or PET/CT scans, are performed to determine the extent of lymph node involvement and to guide biopsy. The definitive diagnosis of Hodgkin lymphoma requires a tissue sample, with excisional lymph node biopsy being the gold standard, as it provides sufficient tissue architecture for accurate histopathological assessment; a core needle biopsy may be considered if excisional biopsy is not feasible. Histopathological examination is essential to differentiate between classic Hodgkin lymphoma (CHL), which is characterized by the presence of Reed-Sternberg cells, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which is identified by 'popcorn-shaped' lymphocyte-predominant (LP) cells. This distinction is critical, as NLPHL has a different clinical course and can transform into diffuse large B-cell lymphoma, affecting prognosis and management. Accurate subtyping based on histology and immunophenotyping informs treatment decisions and long-term follow-up strategies.",
         "Creative Generation",
         "The initial diagnostic approach begins with a thorough health history and physical examination.; The focus is on lymph node regions and systemic symptoms.; Laboratory assessment with blood tests and imaging studies is necessary to evaluate the extent of disease.; A tissue sample is required for definitive diagnosis.; Excisional lymph node biopsy is the gold standard for diagnosis.; Core needle biopsy may be considered if excisional biopsy is not feasible.; Histopathological analysis is crucial to distinguish between classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma.; Classic Hodgkin lymphoma is characterized by Reed-Sternberg cells.; Nodular lymphocyte-predominant Hodgkin lymphoma is characterized by popcorn-shaped cells.; Accurate subtyping guides prognosis and treatment planning.",
         "Most people are diagnosed between ages 15 to 30 or after age 55.; Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy.; Core needle biopsy may be used for diagnosis in some cases.; Health history and physical exam are part of the diagnostic process.; Blood tests and imaging tests are used in the diagnostic workup.; Classic Hodgkin lymphoma (CHL) is characterized by Reed-Sternberg cells.; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is characterized by popcorn-shaped cells.; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)."
        ]
       ],
       "shape": {
        "columns": 7,
        "rows": 166
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>source</th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>question_type</th>\n",
       "      <th>evidence</th>\n",
       "      <th>evidence_relations</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1896</th>\n",
       "      <td>Medical-fe3240a4</td>\n",
       "      <td>Medical</td>\n",
       "      <td>Imagine you are a dermatology attending receiv...</td>\n",
       "      <td>Consult Note:\\n\\nA new patient was referred fo...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient presents with a suspicious lesion ...</td>\n",
       "      <td>BCC most commonly develops in sun-exposed area...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1897</th>\n",
       "      <td>Medical-8f5233d5</td>\n",
       "      <td>Medical</td>\n",
       "      <td>You are a general practitioner drafting a disc...</td>\n",
       "      <td>Discharge Summary:\\n\\nDiagnosis: Basal cell ca...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient was diagnosed with basal cell carc...</td>\n",
       "      <td>BCC most commonly develops in sun-exposed area...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1898</th>\n",
       "      <td>Medical-c9c108e1</td>\n",
       "      <td>Medical</td>\n",
       "      <td>Assume the role of a patient who has just been...</td>\n",
       "      <td>Dear Family,\\n\\nI wanted to let you know that ...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient has been diagnosed with basal cell...</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1899</th>\n",
       "      <td>Medical-bf68d23e</td>\n",
       "      <td>Medical</td>\n",
       "      <td>Rewrite the following scenario into a public h...</td>\n",
       "      <td>Public Health Advisory: Increased Basal Cell C...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>There has been an increase in basal cell carci...</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1900</th>\n",
       "      <td>Medical-fd1b07be</td>\n",
       "      <td>Medical</td>\n",
       "      <td>You are a dermatology intern preparing a refer...</td>\n",
       "      <td>Referral Letter to Oncology:\\n\\nDear Colleague...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient has a history of basal cell carcin...</td>\n",
       "      <td>Recurrence refers to BCC returning to the orig...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2057</th>\n",
       "      <td>Medical-83c906e0</td>\n",
       "      <td>Medical</td>\n",
       "      <td>You are an oncologist preparing a referral let...</td>\n",
       "      <td>Dear Multidisciplinary Team,\\n\\nI am referring...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient is a 45-year-old female.; The pati...</td>\n",
       "      <td>Invasive ductal carcinoma is the most common t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2058</th>\n",
       "      <td>Medical-d168a555</td>\n",
       "      <td>Medical</td>\n",
       "      <td>Imagine you are a medical intern tasked with w...</td>\n",
       "      <td>Discharge Summary:\\n\\nDiagnosis: Stage III inf...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The diagnosis is Stage III inflammatory breast...</td>\n",
       "      <td>Inflammatory breast cancer (IBC) is a rare, ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2059</th>\n",
       "      <td>Medical-fe801cec</td>\n",
       "      <td>Medical</td>\n",
       "      <td>You are a patient advocate tasked with draftin...</td>\n",
       "      <td>Public Health Notice: Protect Yourself—Know th...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>Breast cancer is a carcinoma that starts in th...</td>\n",
       "      <td>Breast cancer is a carcinoma that starts in th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2060</th>\n",
       "      <td>Medical-9210668e</td>\n",
       "      <td>Medical</td>\n",
       "      <td>Transform the clinical facts on metastatic bre...</td>\n",
       "      <td>SOAP Progress Note\\n\\nSubjective: The patient ...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient reports persistent bone pain.; The...</td>\n",
       "      <td>Metastatic breast cancer (MBC) is breast cance...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2061</th>\n",
       "      <td>Medical-5a1e917c</td>\n",
       "      <td>Medical</td>\n",
       "      <td>Assume the role of a genetic counselor. Prepar...</td>\n",
       "      <td>Genetic Counseling Summary:\\n\\nYou have tested...</td>\n",
       "      <td>Creative Generation</td>\n",
       "      <td>The patient has tested positive for a BRCA1 mu...</td>\n",
       "      <td>BRCA1 and BRCA2 mutations increase the risk of...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>166 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                    id   source  \\\n",
       "1896  Medical-fe3240a4  Medical   \n",
       "1897  Medical-8f5233d5  Medical   \n",
       "1898  Medical-c9c108e1  Medical   \n",
       "1899  Medical-bf68d23e  Medical   \n",
       "1900  Medical-fd1b07be  Medical   \n",
       "...                ...      ...   \n",
       "2057  Medical-83c906e0  Medical   \n",
       "2058  Medical-d168a555  Medical   \n",
       "2059  Medical-fe801cec  Medical   \n",
       "2060  Medical-9210668e  Medical   \n",
       "2061  Medical-5a1e917c  Medical   \n",
       "\n",
       "                                               question  \\\n",
       "1896  Imagine you are a dermatology attending receiv...   \n",
       "1897  You are a general practitioner drafting a disc...   \n",
       "1898  Assume the role of a patient who has just been...   \n",
       "1899  Rewrite the following scenario into a public h...   \n",
       "1900  You are a dermatology intern preparing a refer...   \n",
       "...                                                 ...   \n",
       "2057  You are an oncologist preparing a referral let...   \n",
       "2058  Imagine you are a medical intern tasked with w...   \n",
       "2059  You are a patient advocate tasked with draftin...   \n",
       "2060  Transform the clinical facts on metastatic bre...   \n",
       "2061  Assume the role of a genetic counselor. Prepar...   \n",
       "\n",
       "                                                 answer        question_type  \\\n",
       "1896  Consult Note:\\n\\nA new patient was referred fo...  Creative Generation   \n",
       "1897  Discharge Summary:\\n\\nDiagnosis: Basal cell ca...  Creative Generation   \n",
       "1898  Dear Family,\\n\\nI wanted to let you know that ...  Creative Generation   \n",
       "1899  Public Health Advisory: Increased Basal Cell C...  Creative Generation   \n",
       "1900  Referral Letter to Oncology:\\n\\nDear Colleague...  Creative Generation   \n",
       "...                                                 ...                  ...   \n",
       "2057  Dear Multidisciplinary Team,\\n\\nI am referring...  Creative Generation   \n",
       "2058  Discharge Summary:\\n\\nDiagnosis: Stage III inf...  Creative Generation   \n",
       "2059  Public Health Notice: Protect Yourself—Know th...  Creative Generation   \n",
       "2060  SOAP Progress Note\\n\\nSubjective: The patient ...  Creative Generation   \n",
       "2061  Genetic Counseling Summary:\\n\\nYou have tested...  Creative Generation   \n",
       "\n",
       "                                               evidence  \\\n",
       "1896  The patient presents with a suspicious lesion ...   \n",
       "1897  The patient was diagnosed with basal cell carc...   \n",
       "1898  The patient has been diagnosed with basal cell...   \n",
       "1899  There has been an increase in basal cell carci...   \n",
       "1900  The patient has a history of basal cell carcin...   \n",
       "...                                                 ...   \n",
       "2057  The patient is a 45-year-old female.; The pati...   \n",
       "2058  The diagnosis is Stage III inflammatory breast...   \n",
       "2059  Breast cancer is a carcinoma that starts in th...   \n",
       "2060  The patient reports persistent bone pain.; The...   \n",
       "2061  The patient has tested positive for a BRCA1 mu...   \n",
       "\n",
       "                                     evidence_relations  \n",
       "1896  BCC most commonly develops in sun-exposed area...  \n",
       "1897  BCC most commonly develops in sun-exposed area...  \n",
       "1898  Basal cell carcinoma (BCC) is the most common ...  \n",
       "1899  Basal cell carcinoma (BCC) is the most common ...  \n",
       "1900  Recurrence refers to BCC returning to the orig...  \n",
       "...                                                 ...  \n",
       "2057  Invasive ductal carcinoma is the most common t...  \n",
       "2058  Inflammatory breast cancer (IBC) is a rare, ag...  \n",
       "2059  Breast cancer is a carcinoma that starts in th...  \n",
       "2060  Metastatic breast cancer (MBC) is breast cance...  \n",
       "2061  BRCA1 and BRCA2 mutations increase the risk of...  \n",
       "\n",
       "[166 rows x 7 columns]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "a = q[q[\"question_type\"] == \"Creative Generation\"]\n",
    "a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "40f9e44f",
   "metadata": {},
   "outputs": [],
   "source": [
    "Imagine you are a dermatology attending receiving a new patient referral for a suspicious lesion on the face. Write a consult note summarizing the key risk factors, diagnostic steps, and initial management plan for suspected basal cell carcinoma, referencing current clinical practice guidelines."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aed33933",
   "metadata": {},
   "outputs": [],
   "source": [
    "Consult Note:\n",
    "\n",
    "A new patient was referred for evaluation of a suspicious lesion on the left cheek. Key risk factors for basal cell carcinoma (BCC) in this patient include significant cumulative sun exposure, fair skin phenotype, and a personal history of skin cancer. On physical examination, the lesion is located on a sun-exposed area of the face and appears as a shiny, pearly papule with rolled borders, consistent with classic BCC morphology.\n",
    "\n",
    "Diagnostic steps will follow current clinical practice guidelines and include: (1) a comprehensive skin examination to assess for additional lesions, (2) a detailed medical and family history to identify further risk factors or hereditary syndromes, and (3) a skin biopsy of the lesion to establish a definitive diagnosis. Imaging studies may be considered if there is clinical suspicion for perineural invasion or deep tissue involvement.\n",
    "\n",
    "If the diagnosis of BCC is confirmed, the initial management plan will prioritize surgical excision, which is the standard first-line treatment. The patient will be counseled regarding the risk of recurrence and the importance of ongoing surveillance, including annual full skin examinations, as recommended by current guidelines. Additional education will be provided on sun protection and self-skin examination to reduce future risk."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8ceab7c0",
   "metadata": {},
   "outputs": [],
   "source": [
    "The patient presents with a suspicious lesion on the left cheek.; Key risk factors for basal cell carcinoma include significant sun exposure.; Key risk factors for basal cell carcinoma include fair skin.; Key risk factors for basal cell carcinoma include a personal history of skin cancer.; The lesion appears as a shiny, pearly bump with rolled borders.; The diagnostic plan includes a thorough skin exam.; The diagnostic plan includes a detailed medical and family history.; The diagnostic plan includes performing a skin biopsy to confirm basal cell carcinoma.; Imaging may be considered if there is suspicion of deep tissue involvement.; Surgical excision is proposed as the first-line treatment if basal cell carcinoma is confirmed.; The patient will be counseled on recurrence risk.; The patient will be advised on the importance of annual full skin exams for follow-up."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
